Original Article
Sentinel-Node Biopsy or Nodal Observation in Melanoma
N Engl J Med 2006; 355:1307-1317September 28, 2006
- Abstract
Background
We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
Methods
Patients with a primary cutaneous melanoma were randomly assigned to wide excision and postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if nodal micrometastases were detected on biopsy.
Results
Among 1269 patients with an intermediate-thickness primary melanoma, the mean (±SE) estimated 5-year disease-free survival rate for the population was 78.3±1.6% in the biopsy group and 73.1±2.1% in the observation group (hazard ratio for death, 0.74; 95% confidence interval [CI], 0.59 to 0.93; P=0.009). Five-year melanoma-specific survival rates were similar in the two groups (87.1±1.3% and 86.6±1.6%, respectively). In the biopsy group, the presence of metastases in the sentinel node was the most important prognostic factor; the 5-year survival rate was 72.3±4.6% among patients with tumor-positive sentinel nodes and 90.2±1.3% among those with tumor-negative sentinel nodes (hazard ratio for death, 2.48; 95% CI, 1.54 to 3.98; P<0.001). The incidence of sentinel-node micrometastases was 16.0% (122 of 764 patients), and the rate of nodal relapse in the observation group was 15.6% (78 of 500 patients). The corresponding mean number of tumor-involved nodes was 1.4 in the biopsy group and 3.3 in the observation group (P<0.001), indicating disease progression during observation. Among patients with nodal metastases, the 5-year survival rate was higher among those who underwent immediate lymphadenectomy than among those in whom lymphadenectomy was delayed (72.3±4.6% vs. 52.4±5.9%; hazard ratio for death, 0.51; 95% CI, 0.32 to 0.81; P=0.004).
Conclusions
The staging of intermediate-thickness (1.2 to 3.5 mm) primary melanomas according to the results of sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases whose survival can be prolonged by immediate lymphadenectomy. (ClinicalTrials.gov number, NCT00275496.)
Media in This Article
Video
Sentinel Node Biopsy for Management of Regional Nodes in Primary Cutaneous Melanoma.
Figure 1
Trial Design (Panel A) and Enrollment and Outcomes (Panel B).Article Activity
- Article
Video
Sentinel Node Biopsy for Management of Regional Nodes in Primary Cutaneous Melanoma.
In most patients with clinically localized melanoma of intermediate thickness, wide resection is curative, but metastasis to regional nodes develops in 15 to 20%. Since metastasis to a regional node is the most important prognostic factor in early-stage melanoma,1,2 immediate (elective) lymphadenectomy has been advocated to improve tumor staging and possibly survival.3,4 However, this approach exposes patients to complications resulting from the procedure and has not been shown to improve overall survival5; in a minority of patients with occult nodal metastases, however, it may have benefit.3,4
We developed a technique for lymphatic mapping and sentinel-node biopsy as a minimally invasive surgical alternative to elective lymph-node dissection for nodal staging to identify patients with occult nodal metastases who might benefit from total lymphadenectomy.6-9 Vital blue dye and radiocolloid were used to map the lymphatic drainage from a primary cutaneous melanoma to a tumor-draining regional lymph node (or nodes). (A video of the mapping and surgical procedures is available with the full text of this article at www.nejm.org.) Lymphatic mapping shows the anatomical path of metastatic melanoma cells from the primary melanoma and accurately identifies for pathological scrutiny the node, known as the sentinel node, that receives lymph directly from a primary melanoma. The sentinel node, as compared with other regional nodes, is most susceptible to the immunosuppressive influences of the tumor10 and is the initial site of regional nodal metastases. If the sentinel node is free of melanoma, the remaining nodes in the regional basin will also be tumor-free.8,11-13 If, however, the sentinel node contains metastases, other nodes in the basin may also contain metastatic melanoma. The American Joint Committee on Cancer (AJCC) has incorporated the tumor status of the sentinel node into its staging system for melanoma.14 Moreover, the tumor status of the sentinel node accurately reflects the status of the regional nodes in breast, colon, and lung cancers.
The Multicenter Selective Lymphadenectomy Trial (MSLT) was initiated on January 4, 1994, to study the usefulness of sentinel-node biopsy in the identification of patients with clinically occult nodal metastases and to evaluate the clinical effect of immediate, complete lymphadenectomy in patients with tumor-positive sentinel nodes. Enrollment in the trial closed in March 2002.15,16 After the third planned interim analysis, the data and safety monitoring committee recommended publication of data with implications for the management of early-stage melanoma. The data on surgical complications and the accuracy of sentinel-node biopsy have been published elsewhere16; this report presents interim data on the efficacy end points of the trial.
Methods
Trial Design
Patients with clinically localized primary cutaneous melanoma were randomly assigned to undergo either wide excision and sentinel-node biopsy (the biopsy group) or wide excision and postoperative observation of the regional nodal basin (the observation group). In the observation group, delayed lymphadenectomy was performed if nodal recurrences became clinically detectable; in the biopsy group, immediate lymphadenectomy was performed if micrometastases were detected in the sentinel-node biopsy. The sentinel nodes were examined in multiple permanent sections of tissue stained with hematoxylin and eosin and by immunohistochemical analysis with the use of antibodies to the melanoma-associated antigens S-100, HMB-45, and MART-1 or Melan-A.8,15,16 If the node was found to contain metastases, a complete lymphadenectomy was performed shortly thereafter (Figure 1AFigure 1
Trial Design (Panel A) and Enrollment and Outcomes (Panel B).).Patients
Eligible patients had invasive primary cutaneous melanomas that were classified as Clark level III with a Breslow thickness of 1 mm or more, or as Clark level IV or V with any Breslow thickness. The inclusion and exclusion criteria of the study have been described elsewhere.16 Patients with melanomas 1.2 to 3.5 mm in thickness were selected as the primary study group, because pretrial statistical modeling on the basis of data from the prospective melanoma database of the John Wayne Cancer Institute1,17 indicated that the timing of a complete lymphadenectomy (immediate elective surgery or delayed until nodal relapse) probably affects survival among patients with melanomas that are within this range.
Patients who gave written informed consent to participate were randomly assigned to biopsy or observation in a 60:40 ratio. All patients underwent wide excision of the primary melanoma16 and were monitored postoperatively by means of clinical examination, blood tests, and chest radiography at least every 3 months during the first 2 years, every 4 months during year 3, every 6 months during years 4 and 5, and then annually until year 10.
Statistical Analysis
The primary end point was melanoma-specific survival (survival until death from melanoma). Other planned end points were disease-free survival before a first recurrence at any site (survival without evidence of recurrence or metastasis); melanoma-specific survival and disease-free survival with tumor-positive or tumor-negative sentinel nodes; the incidence of nodal metastasis as identified on pathological examination of a specimen of the sentinel node or on clinical examination during observation or after a sentinel-node biopsy with a false negative result; and survival with or without nodal metastases detected on biopsy or during observation. Follow-up and survival were calculated from the date of randomization to the date of the last examination or death.
Randomization was carried out centrally, in a stratified fashion, in random permuted blocks of four, six, and eight patients. The stratification factors were Breslow thickness (1.20 to 1.79 mm vs. 1.80 to 3.50 mm) and the primary site of the melanoma (arm or leg vs. other site). The initial planned sample size of 900 patients was calculated on the basis of a type I error rate of 5%, and a statistical power of 90% to detect melanoma-specific survival, and the sample size was derived by simulating stratification into four subgroups with negligible loss to follow-up (5%). The treatment effect was the Kaplan–Meier estimate of melanoma-specific survival among patients with the same prognostic factors who underwent early, as compared with delayed, lymphadenectomy (on the basis of data from the melanoma database of the John Wayne Cancer Institute).15,17 At the second of four planned interim analyses, the sample size was increased to 1200 patients, because the distribution of those entering the trial was skewed toward patients at lower risk for recurrence or death, and therefore there were fewer events than expected. The final number of patients undergoing randomization was 1347, to balance the accrual among participating centers and to include patients who had given informed consent before enrollment was closed.
The planned statistical analysis for the primary and secondary end points was carried out by the log-rank test. The censoring of deaths not due to melanoma and the treatment of such deaths as a competing risk yielded closely similar results for the primary end point. The Kaplan–Meier method was used to estimate mean (±SE) 5-year melanoma-specific survival and disease-free survival for the population, and the results were reported at particular times after randomization. A Cox proportional-hazards regression model was used that included sentinel-node status, Breslow thickness, Clark level, anatomic site of the primary melanoma, presence or absence of ulceration, age, and sex. The baseline demographic and clinical characteristics of the patients and the pathological factors were summarized with the use of descriptive statistics and were compared with the use of a t-test or the chi-square test. The numbers of tumor-involved nodes in the two study groups were compared by the Wilcoxon rank-sum test, and the distribution of nodal stage according to the AJCC classification system was compared by the chi-square test. All analyses were performed with the use of SAS software, version 9.1, and all reported P values are two-sided with a value of less than 0.05 considered to indicate statistical significance.
Comparisons of overall disease-free survival and melanoma-specific survival between the two study groups were based on 1269 patients who received the assigned treatment. The analysis of the subgroups of patients with nodal metastases was based on 764 patients in the biopsy group for whom complete information on nodal status was available and 500 patients in the observation group. Parallel analyses according to the intention-to-treat principle included 1327 patients; the results were consistent with those of the analysis involving 1269 patients.
Results
Between January 20, 1994, and March 29, 2002, 1347 patients who underwent randomization (those with primary melanomas 1.2 to 3.5 mm in thickness) were enrolled. Nineteen patients dropped out after undergoing randomization and 1 patient was ineligible because of the presence of clinically palpable lymph nodes; the analysis includes the remaining 1327 patients (Figure 1B): 221 from North America, 386 from Europe, and 720 from Australia. All patients had primary melanomas with closely similar characteristics (Table 1Table 1
Baseline Characteristics of the Patients.). During this period, 654 patients with lesions thinner than 1.2 mm and thicker than 3.5 mm entered the initial MSLT study; data on these patients were used to evaluate surgical morbidity and accuracy, as previously reported.16 Survival Rates
After a median follow-up of 59.8 months, the frequency of relapse at any site was 26.8% (134 of 500 patients) in the observation group and 20.7% (159 of 769) in the biopsy group (Table 1). The disease-free survival rate was significantly higher in the biopsy group than in the observation group at 5 years (78.3±1.6% vs. 73.1±2.1%; hazard ratio, 0.74; 95% confidence interval [CI], 0.59 to 0.93; P=0.009) (Figure 2AFigure 2
Disease-free Survival and Melanoma-Specific Survival, According to the Type of Treatment and the Tumor Status of the Sentinel Node.). Among the 1269 patients who received the assigned treatment, the rate of death from melanoma (melanoma-specific death) was similar in the two groups at 5 years: 13.8% (69 of 500 patients) in the observation group and 12.5% (96 of 769 patients) in the biopsy group. The melanoma-specific survival rate was also similar in the two groups: 90.1±1.4% and 93.2±0.9%, respectively, at 3 years, and 86.6±1.6% and 87.1±1.3%, respectively, at 5 years (hazard ratio, 0.92; 95% CI, 0.67 to 1.25; P=0.58) (Figure 2B).Prognosis and Sentinel-Node Status
The melanoma-specific mortality rate in the biopsy group was 9.7% (62 of 642 patients) when the sentinel node was tumor-free and 26.2% (32 of 122) if the node contained metastases. At 5 years, the estimated disease-free survival rate was 53.4±4.9% if the sentinel node contained metastases and 83.2±1.6% if the node was free of metastases (P<0.001) (Figure 2C); the corresponding values for melanoma-specific survival were 72.3±4.6% and 90.2±1.3%, respectively (P<0.001) (Figure 2D). In the biopsy group, among patients with tumor-positive sentinel nodes, as compared with patients with tumor-free sentinel nodes, the hazard ratio for death was 2.48 (95% CI, 1.54 to 3.98; P<0.001), and the hazard ratio for recurrence of melanoma was 3.04 (95% CI, 2.11 to 4.39; P<0.001) in the multivariate Cox model that included the Clark level, Breslow thickness, presence or absence of ulceration, site of primary melanoma, age, and sex (Table 2Table 2
Cox Multivariate Analysis of the Prognostic Value of Various Factors for Patients Assigned to Sentinel-Node Biopsy.).Presence of Nodal Metastases
After a median follow-up of 59.8 months, 78 of the 500 patients in the observation group (15.6%) had a clinical relapse detected in regional nodes (Table 1), with a cumulative predicted incidence of 18.5±2.1% according to the Kaplan–Meier method after 8 years of follow-up (Figure 3AFigure 3
Melanoma-Specific Survival, According to the Presence or Absence of Nodal Metastases and Time to Nodal and Local or In-Transit Recurrence.). The median time to clinical detection of nodal relapse among the 78 patients was 1.33 years (95% CI, 1.02 to 1.76).The histopathological status of the sentinel node was available for 764 of 769 patients in the biopsy group: in 122 (16.0%) of these patients, the specimens were tumor-positive. After a median follow-up of 59.8 months, a nodal recurrence was detected in 26 patients (3.4%) with a tumor-negative sentinel node on biopsy. Thus, the proportion of patients with nodal metastases in the biopsy group was 19.4% (148 of 764) (Figure 3B). The rate of false negative results was 3.4%, which is within the range predicted on the basis of our experience (1.7%)18 and reported in the literature (1.5%).19
Nodal Metastases and Survival
The distribution of prognostic factors between the two groups among patients with nodal metastases did not differ significantly except in relation to age (Table 1). After a median of 48.4 months, the rate of melanoma-specific deaths in the biopsy group was 26.2% (32 of 122 patients) among those who underwent immediate lymphadenectomy, as compared with 48.7% (38 of 78) in the observation group among those who underwent delayed lymphadenectomy. The corresponding rates of 5-year survival in these prespecified subgroups were 72.3±4.6% and 52.4±5.9%, respectively (hazard ratio for death, 0.51; 95% CI, 0.32 to 0.81; P=0.004 by the log-rank test and P=0.007 by the Cox model) (Figure 3B).
Survival rates among patients with a nodal recurrence after a false negative result on biopsy were similar to those among patients with nodal relapse during observation (estimated 3-year survival, 68.4±9.3% and 64.9±5.4%, respectively; P=0.60) (Figure 3B); the 5-year survival rate was significantly higher in the biopsy group among patients with nodal metastases detected on biopsy or after a false negative biopsy than in the observation group among those with nodal recurrence (66.2±4.4% vs. 54.2±5.9%; hazard ratio for death, 0.62; 95% CI, 0.40 to 0.95; P=0.02) (Figure 3B).
Nodal metastases did not occur in 616 patients in the biopsy group and in 422 patients in the observation group. The 5-year survival rate in the two groups was similar (92.9±1.3% and 92.4±1.2%, respectively; P=0.98) (Figure 3C), indicating that survival among patients without regional nodal metastases was unaffected by sentinel-node biopsy. The frequency of local or in-transit (regional endolymphatic) recurrence did not differ significantly at 5 years between the biopsy and observation groups (7.7±1.0% and 8.4±1.3%, respectively; P=0.38) (Figure 3D).
Tumor-Involved Regional Nodes
AJCC nodal stage (defined according to the number of tumor-positive nodes), which is a surrogate for the risk of death from melanoma,2,14 differed according to whether nodal metastases were identified during observation or on biopsy: 39.2% of patients with metastasis in the observation group were in nodal stage 1, as compared with 70.5% of such patients in the biopsy group (P<0.001); the proportions in nodal stage 3 were 25.7% and 1.6%, respectively (P<0.001) (Table 1). In the observation group, the mean (±SE) number of clinically detectable tumor-positive nodes in patients who underwent delayed lymphadenectomy was 3.3±0.5; in the biopsy group, the mean number of clinically occult tumor-positive nodes among those who underwent immediate lymphadenectomy was 1.4±0.1 (P<0.001) (Table 1). Patients with nodal relapse after a false negative result on biopsy had more tumor-containing nodes than did those who underwent immediate lymphadenectomy after a positive result on biopsy (4.3±1.6 vs. 1.4±0.1) (Table 1).
Discussion
This third interim analysis of the results of the MSLT provides data of practical importance in the treatment of patients with melanoma. Our results confirm that sentinel-node biopsy has a high value for staging clinically localized, intermediate-thickness melanoma and provides a more accurate basis for formulating a prognosis than do standard demographic and histopathological factors (Table 2). The presence or absence of tumor cells in the sentinel node is critical to both accurate AJCC staging14 and decisions regarding lymphadenectomy and adjuvant therapy. Moreover, long-term follow-up of the patients in the MSLT indicates that experience gained from performing 55 or more sentinel-node biopsies16 is required to carry out the procedure in a manner that reliably reduces nodal relapse.15-17
This interim analysis did not reveal a significant difference in melanoma-specific survival between the two study groups, but it did show that biopsy with immediate lymphadenectomy prolonged disease-free survival and diminished the trauma of recurrence (Figure 2A).20,21 Observation allows nodal micrometastases to enlarge22 and spread to other nodes, thereby increasing the risk of distant metastases and decreasing the chance of long-term survival2,15-17,23 (Table 1 and Figure 3B). Immediate lymphadenectomy in patients with subclinical sentinel-node metastases increased the melanoma-specific 5-year survival rate, as compared with delayed lymphadenectomy for clinically detected nodal relapse (72.3% vs. 52.4%; hazard ratio for death, 0.51; 95% CI, 0.32 to 0.81; P=0.004) (Figure 3B). We did not expect that the removal of tumor-free regional nodes would improve survival — indeed, biopsy did not improve survival among patients without nodal metastases (Figure 3C).
Our findings are consistent with those of analyses of data of single-center1 and international2 studies and those of a smaller prospective, randomized trial conducted by the World Health Organization Melanoma Program3: all show improved long-term survival when lymphadenectomy is performed for microscopic rather than clinically detectable nodal disease. Our findings provide support for the matched-pair analyses by the John Wayne Cancer Institute, which showed a survival benefit from immediate lymphadenectomy, as compared with delayed lymphadenectomy, in patients with nodal metastases.17 We also confirmed that the incidence of local or in-transit metastases was not increased among patients treated with sentinel-node biopsy.24-26
Because occult nodal metastases could not be identified before patients entered the trial, we relied on randomization to ensure a balance between the two study groups. As shown in Table 1, this balance was achieved with respect to Clark level, Breslow thickness, and the presence or absence of ulceration — features that correlate with occult nodal metastases.8,11,13,16,23 The striking similarity between the incidence of sentinel-node micrometastases and the frequency of nodal relapse during observation further suggests a balanced distribution: the projected frequency of palpable nodal relapse (±SE) at 8 years was 18.5±2.1% in the observation group (Figure 3A), whereas in the biopsy group the incidence of sentinel-node micrometastases or nodal relapse after a false negative result on biopsy was 19.4% (Table 1).
Our results provide evidence that occult micrometastases in the sentinel node usually progress to aggressive regional or distant disease. Were this not the case, we would not have seen an overall improvement in disease-free survival among the patients assigned to biopsy (Figure 2A), nor would there have been a significant difference in the rate of nodal relapse between patients with tumor-negative sentinel nodes and those assigned to observation (4.0% [26 of 642 patients] vs. 15.6% [78 of 500], P<0.001) (Figure 3A). The influence of the tumor status of the sentinel node on disease-free survival and melanoma-specific survival (Figure 2C and 2D) (P<0.001 for both comparisons) also indicates the aggressiveness of sentinel-node micrometastases.
Our findings indicate that sentinel-node biopsy has staging and prognostic value in patients with intermediate-thickness melanoma and, coupled with immediate complete lymphadenectomy, improves survival among patients with a tumor-positive sentinel node. In patients with primary melanomas that are 1.2 to 3.5 mm in thickness, sentinel-node biopsy should be preferred to observation.
Supported by a grant (CA 29605, to Dr. Morton) from the National Cancer Institute.
No potential conflict of interest relevant to this article was reported.
We are indebted to the patients who participated in this study; to the coordinating group at the John Wayne Cancer Institute: Lisa van Kreuningen, Stacey Stern, Amber Nichols, Paul Linke, Angelica Gurrola, and Laura Janis, without whose assistance and support in monitoring and trial and data management the study would not have been possible; and to Duan Ren Wen for pathological expertise.
Source Information
From the Departments of Surgical Oncology (D.L.M., R. Essner) and Biostatistics (R. Elashoff, H.-J.W.), John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA; the Sydney Melanoma Unit, Royal Prince Alfred Hospital, Camperdown, NSW, Australia (J.F.T.); the Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles (A.J.C.); the Department of Surgical Oncology, National Cancer Institute, Naples, Italy (N.M.); the Department of Biostatistics, University of California at Los Angeles, Los Angeles (R. Elashoff, H.-J.W.); the Department of Surgery, Netherlands Cancer Institute, Amsterdam (O.E.N.); the Department of Surgery, New York University School of Medicine, New York (D.F.R.); the Department of Surgical Oncology, University Medical Center Groningen and Groningen University, Groningen, the Netherlands (H.J.H.); the Department of Surgery, Millard Fillmore Hospital, Buffalo, NY (C.P.K.); the Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (D.S.R.); the Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia (B.J.C.); and the Department of Nuclear Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles (E.C.G.).
Address reprint requests to Dr. Morton at the John Wayne Cancer Institute at Saint John's Health Center, 2200 Santa Monica Blvd., Santa Monica, CA 90404, or at mortond@jwci.org.
Members of the Multicenter Selective Lymphadenectomy Trial (MSLT) Group are listed in the Appendix.
Appendix
The MSLT participants were as follows: Independent data and safety monitoring committee — J. Kirkwood (chair), J. Daly, M. Kutner, M. Mihm, G. Smith, M. Urist, N. Beegun (patient advocate); Trial sites and principal investigators — Sydney Melanoma Unit, Sydney, Australia: J.F. Thompson; Istituto Nazionale dei Tumori de Napoli, Naples, Italy: N. Mozzillo; Netherlands Cancer Institute, Amsterdam: O.E. Nieweg; New York University, New York: D.F. Roses; University Medical Center Groningen and University of Groningen, Groningen, the Netherlands: H.J. Hoekstra; Millard Fillmore Hospital, Buffalo, NY: C.P. Karakousis; H. Lee Moffit Cancer Center, Tampa, FL: D.S. Reintgen; University of California and Mt. Zion Medical Center, San Francisco: S.P.L. Leong; Royal Adelaide Hospital, Adelaide, Australia: B.J. Coventry; Roswell Park Cancer Institute, Buffalo, NY: W. Kraybill; Princess Alexandra Hospital, Brisbane, Australia: M. Smithers; Henry Ford Hospital, Detroit: S.D. Nathanson; University of Texas Southwestern Medical Center at Dallas, Dallas: J.F. Huth; University of Hawaii at Manoa, Honolulu: J.H. Wong; University of Pennsylvania, Philadelphia: D.L. Fraker; Tom Baker Cancer Centre, Calgary, AB, Canada: W. Temple; City Hospital of Nürnberg, Nürnberg, Germany: E. Paul; John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA: D.L. Morton.
- References
References
1
Morton DL ,Wanek L ,Nizze JA ,Elashoff RM ,Wong JH . Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-499
CrossRef | Web of Science | Medline2
Balch CM ,Soong SJ ,Gershenwald JE , et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634
Web of Science | Medline3
Cascinelli N ,Morabito A ,Santinami M ,MacKie RM ,Belli F . Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet 1998;351:793-796
CrossRef | Web of Science | Medline4
Balch CM ,Soong S ,Ross MI , et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97
CrossRef | Web of Science | Medline5
Veronesi U ,Adamus J ,Bandiera DC , et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977;297:627-630
Full Text | Web of Science | Medline6
Morton D, Cagle L, Wong J, et al. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure for clinical stage I melanoma. Presented at the 42nd Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 20–22, 1990.
7
Wong JH ,Cagle LA ,Morton DL . Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991;214:637-641
CrossRef | Web of Science | Medline8
Morton DL ,Wen DR ,Wong JH , et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399
CrossRef | Web of Science | Medline9
Morton DL ,Cochran AJ . The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 2004;151:308-319
CrossRef | Web of Science | Medline10
Cochran AJ ,Morton DL ,Stern S ,Lana AM ,Essner R ,Wen DR . Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001;14:604-608
CrossRef | Web of Science | Medline11
Thompson JF ,McCarthy WH ,Bosch CM , et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260
CrossRef | Web of Science | Medline12
Reintgen D ,Cruse CW ,Wells K , et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-767
CrossRef | Web of Science | Medline13
Gershenwald JE ,Thompson W ,Mansfield PF , et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983
Web of Science | Medline14
Balch CM ,Buzaid AC ,Soong SJ , et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648
Web of Science | Medline15
Morton DL ,Thompson JF ,Essner R , et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230:453-463
CrossRef | Web of Science | Medline16
Morton DL ,Cochran AJ ,Thompson JF , et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311
Web of Science | Medline17
Morton DL ,Hoon DS ,Cochran AJ , et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-549
Web of Science | Medline18
Zogakis TG ,Essner R ,Wang HJ , et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg 2005;140:865-871
CrossRef | Web of Science | Medline19
Chao C ,Wong SL ,Ross MI , et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002;184:520-524
CrossRef | Web of Science | Medline20
Andersen BL ,Shapiro CL ,Farrar WB ,Crespin T ,Wells-Digregorio S . Psychological responses to cancer recurrence. Cancer 2005;104:1540-1547
CrossRef | Web of Science | Medline21
Kilbridge KL ,Weeks JC ,Sober AJ , et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001;19:812-823
Web of Science | Medline22
Cochran AJ ,Lana AMA ,Wen D-R . Histomorphometry in the assessment of prognosis in stage II malignant melanoma. Am J Surg Pathol 1989;13:600-604
CrossRef | Web of Science | Medline23
Cochran AJ ,Wen DR ,Huang RR ,Wang HJ ,Elashoff R ,Morton DL . Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004;17:747-755
CrossRef | Web of Science | Medline24
van Poll D ,Thompson JF ,Colman MH , et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608
CrossRef | Web of Science | Medline25
Pawlik TM ,Ross MI ,Thompson JF ,Eggermont AM ,Gershenwald JE . The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005;23:4588-4590
CrossRef | Web of Science | Medline26
Kang JC ,Wanek LA ,Essner R ,Faries MB ,Foshag LJ ,Morton DL . Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005;23:4764-4770
CrossRef | Web of Science | Medline
- Citing Articles (416)
Citing Articles
1
Christopher English, Warren C. Hammert. (2012) Cutaneous Malignancies of the Upper Extremity. The Journal of Hand Surgery 37:2, 367-377
CrossRef2
Rebecca Kleinerman, Omar A. Ibrahimi, Daniel B. Eisen. (2012) Letter: Re: Sentinel Node Biopsy Should Be Offered in Thin Melanoma with Mitotic Rate Greater than One. Dermatologic Surgery 38:2, 290-292
CrossRef3
William Tuong, Lily S. Cheng, April W. Armstrong. (2012) Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. Dermatologic Clinics 30:1, 113-124
CrossRef4
Toufic J. Maalouf, Gilles Dolivet, Karine S. Angioi, Agnes Leroux, Pascal Genin, Jean-Luc George. (2012) Sentinel Lymph Node Biopsy in Patients With Conjunctival and Eyelid Cancers. Ophthalmic Plastic & Reconstructive Surgery 28:1, 30-34
CrossRef5
Michael S. Sabel, John D. Rice, Kent A. Griffith, Lori Lowe, Sandra L. Wong, Alfred E. Chang, Timothy M. Johnson, Jeremy M. G. Taylor. (2012) Validation of Statistical Predictive Models Meant to Select Melanoma Patients for Sentinel Lymph Node Biopsy. Annals of Surgical Oncology 19:1, 287-293
CrossRef6
A. Duvernay, B. Henault, M.A. Danino, O. Trost, S. Dalac, M.-H. Aubriot-Lorton, N. Zwetyenga. (2012) Les complications liées à la technique du ganglion sentinelle dans le mélanome cutané. Étude rétrospective à partir de 127 cas. Annales de Chirurgie Plastique Esthétique
CrossRef7
Benjamin A. S. Gurney, Clare Schilling, Venkata Putcha, Lee W. Alkureishi, Amezaga J. Alvarez, Vivi Bakholdt, Luis Barbier Herrero, Luigi Barzan, Anders Bilde, Elisabeth Bloemena, Carmen Camarero Salces, Paolo Dalla Palma, Remco de Bree, Didier Dequanter, Gilles Dolivet, Davide Donner, Geke B. Flach, Manuel Fresno, Cesare Grandi, Stephan Haerle, Gerhard F. Huber, Keith Hunter, George Lawson, Agnes Leroux, Phillippe H. Lothaire, Gerard Mamelle, Enrico M. Silini, Romina Mastronicola, Edward W. Odell, Michael J. O'Doherty, Tito Poli, Siavash Rahimi, Gary L. Ross, J. Santamaria Zuazua, Simone Santini, Lars Sebbesen, Taimur Shoaib, Philip Sloan, Jens Ahm Sorensen, David S. Soutar, Marianne H. Therkildsen, Maurizio Giovanni Vigili, Pedro M. Villarreal, Christian von Buchwald, Jochen A. Werner, Susanne Wiegand, Mark McGurk. (2012) Implications of a positive sentinel node in oral squamous cell carcinoma. Head & Neckn/a-n/a
CrossRef8
Antonio Piñero, Carlos Torre, Jorge Martínez-Escribano, Juana Campillo, Manuel Canteras, Francisco Nicolás. (2011) Multiple Lymphatic Basin Drainage from Cutaneous Melanoma as a Prognostic Factor. World Journal of Surgery
CrossRef9
I. M. Ising, A. Bembenek, R. Gutzmer, F. Köckerling, K. T. Moesta. (2011) Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection. Langenbeck's Archives of Surgery
CrossRef10
Jutta Engel, Rebecca T. Emeny, Dieter Hölzel. (2011) Positive lymph nodes do not metastasize. Cancer and Metastasis Reviews
CrossRef11
Christy Y. Chai, Jonathan S. Zager, Margaret M. Szabunio, Suroosh S. Marzban, Alec Chau, Robert M. Rossi, Vernon K. Sondak. (2011) Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma. Annals of Surgical Oncology
CrossRef12
Torsten Hinz, Hojjat Ahmadzadehfar, Anja Wierzbicki, Tobias Höller, Jörg Wenzel, Hans-Jürgen Biersack, Thomas Bieber, Monika-H. Schmid-Wendtner. (2011) Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up. European Journal of Nuclear Medicine and Molecular Imaging
CrossRef13
R. Botella-Estrada, E. Nagore. (2011) Estado actual del ganglio centinela en el melanoma. Actas Dermo-Sifiliográficas 102:10, 749-753
CrossRef14
Linda C. Harlan, Charles F. Lynch, Rachel Ballard-Barbash, Christopher Zeruto. (2011) Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study. Melanoma Research 21:6, 547-554
CrossRef15
P. Quaglino, S. Ribero, S. Osella-Abate, L. Macrì, M. Grassi, V. Caliendo, S. Asioli, A. Sapino, G. Macripò, P. Savoia, M.G. Bernengo. (2011) Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: A single centre observational cohort study. Surgical Oncology 20:4, 259-264
CrossRef16
Victoria Lyo, Adnan A. Jaigirdar, Suresh Thummala, Eugene T. Morita, Patrick A. Treseler, Mohammed Kashani-Sabet, Stanley P. L. Leong. (2011) In-Transit Intramammary Sentinel Lymph Nodes From Malignant Melanoma of the Trunk. Annals of Surgery1
CrossRef17
M. Fawzy, J. Garioch, L. Igali, J.V. Skrypniuk, M.D.S. Moncrieff. (2011) Setting up an effective and efficient Sentinel Node Biopsy Service for Malignant Melanoma within the NHS. Journal of Plastic, Reconstructive & Aesthetic Surgery
CrossRef18
Mark B. Faries, Donald L. Morton. (2011) Staging of Regional Nodes in Pulmonary Malignancies. Annals of Surgical Oncology
CrossRef19
Kristina Rue Nielsen, Annette H. Chakera, Birger Hesse, Richard A. Scolyer, Jonathan F. Stretch, John F. Thompson, Michael B. Nielsen, Roger F. Uren, Peter S. Oturai. (2011) The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging 38:11, 1999-2004
CrossRef20
Carrie K. Chu, Keith A. Delman, Grant W. Carlson, Andrea C. Hestley, Douglas R. Murray. (2011) Inguinopelvic Lymphadenectomy Following Positive Inguinal Sentinel Lymph Node Biopsy in Melanoma: True Frequency of Synchronous Pelvic Metastases. Annals of Surgical Oncology 18:12, 3309-3315
CrossRef21
Anne-Sophie Bats, Annie Buénerd, Denis Querleu, Eric Leblanc, Emile Daraï, Philippe Morice, Henri Marret, Florence Gillaizeau, Patrice Mathevet, Fabrice Lécuru. (2011) Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: A prospective, multicenter study. Gynecologic Oncology 123:2, 230-235
CrossRef22
F. Wright, K. Spithoff, A. Easson, C. Murray, J. Toye, D. McCready, T. Petrella. (2011) Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. Clinical Oncology 23:9, 572-578
CrossRef23
Travis E. Grotz, Aaron S. Mansfield, James W. Jakub, Svetomir N. Markovic. (2011) Regional lymphatic immunity in melanoma. Melanoma Research1
CrossRef24
Nick Verwer, Richard A. Scolyer, Roger F. Uren, Julie Winstanley, Philip T. Brown, Johannes H. W. Wilt, John F. Thompson. (2011) Treatment and Prognostic Significance of Positive Interval Sentinel Nodes in Patients with Primary Cutaneous Melanoma. Annals of Surgical Oncology 18:12, 3292-3299
CrossRef25
J.M.G. Larkin, M.E. Gore. (2011) Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-negative Melanoma of the Trunk or Extremities. Clinical Oncology 23:9, 569-571
CrossRef26
Christopher K. Bichakjian, Allan C. Halpern, Timothy M. Johnson, Antoinette Foote Hood, James M. Grichnik, Susan M. Swetter, Hensin Tsao, Victoria Holloway Barbosa, Tsu-Yi Chuang, Madeleine Duvic, Vincent C. Ho, Arthur J. Sober, Karl R. Beutner, Reva Bhushan, Wendy Smith Begolka. (2011) Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology 65:5, 1032-1047
CrossRef27
Hiroaki IWATA, Hideki KAMIYA, Yasuo KITAJIMA. (2011) False-negative sentinel lymph node biopsy resulting from obstruction of lymphatic basin by nodal metastasis: A case report of malignant melanoma. The Journal of Dermatology 38:11, 1121-1124
CrossRef28
Eijun Itakura, Rong-Rong Huang, Duan-Ren Wen, Alistair J. Cochran. (2011) “Stealth” Melanoma Cells in Histology-negative Sentinel Lymph Nodes. The American Journal of Surgical Pathology 35:11, 1657-1665
CrossRef29
Keun Won Ryu, Bang Wool Eom, Byung-Ho Nam, Jun Ho Lee, Myeong Cherl Kook, Il Ju Choi, Young-Woo Kim. (2011) Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta-analysis of feasibility studies. Journal of Surgical Oncology 104:6, 578-584
CrossRef30
Jens Ulrich, Alexander JC van Akkooi, Alexander MM Eggermont, Christiane Voit. (2011) New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). Expert Review of Anticancer Therapy 11:11, 1693-1701
CrossRef31
Lori A. Pollack, Jun Li, Zahava Berkowitz, Hannah K. Weir, Xiao-Cheng Wu, Umed A. Ajani, Donatus U. Ekwueme, Chunyu Li, Brian P. Pollack. (2011) Melanoma survival in the United States, 1992 to 2005. Journal of the American Academy of Dermatology 65:5, S78-S86
CrossRef32
Takamichi Ito, Yoichi Moroi, Junna Oba, Takeshi Nakahara, Satoshi Takeuchi, Hiroshi Uchi, Masakazu Takahara, Teiichi Masuda, Masutaka Furue. (2011) The prognostic value of a reverse transcriptase-PCR assay of sentinel lymph node biopsy for patients with cutaneous melanoma. Melanoma Research1
CrossRef33
Ingo Stoffels, Hannah von der Stück, Christian Boy, Thorsten Pöppel, Nina Körber, Maren Weindorf, Joachim Dissemond, Dirk Schadendorf, Joachim Klode. (2011) Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermato-oncology. JDDG: Journal der Deutschen Dermatologischen Gesellschaftno-no
CrossRef34
Emma C. Rossi, Anastasia Ivanova, John F. Boggess. (2011) Robotically assisted fluorescence-guided lymph node mapping with ICG for gynecologic malignancies: A feasibility study. Gynecologic Oncology
CrossRef35
J. Klode, T. Poeppel, C. Boy, S. Mueller, D. Schadendorf, A. Körber, I. Stoffels, J. Dissemond. (2011) Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. Journal of the European Academy of Dermatology and Venereology 25:10, 1213-1221
CrossRef36
Adriana Cordova, Salvatore D’Arpa, Francesca Toia, Claudia Liuzza, Gaetana Rinaldi, Francesco Moschella. (2011) Sentinel node biopsy for malignant melanoma: a staging procedure only?. European Journal of Plastic Surgery 34:5, 359-366
CrossRef37
I. Koskivuo, M. Hernberg, P. Vihinen, S. Virolainen, L. Talve, M. Seppänen, T. Vahlberg, T. Jahkola. (2011) Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. British Journal of Surgery 98:10, 1400-1407
CrossRef38
Henk G. van der Poel, Tessa Buckle, Oscar R. Brouwer, Renato A. Valdés Olmos, Fijs W.B. van Leeuwen. (2011) Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer. European Urology 60:4, 826-833
CrossRef39
Hidde J. Veenstra, Michel J.W.M. Wouters, Bin B.R. Kroon, Renato. A. Valdés Olmos, Omgo E. Nieweg. (2011) Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. Journal of Surgical Oncology 104:5, 454-457
CrossRef40
Christiane A. Voit, Alexander J.C. van Akkooi, Gregor Schäfer-Hesterberg, Wolfram Sterry, Alexander M.M. Eggermont. (2011) Multimodality approach to the sentinel node. Melanoma Research 21:5, 450-456
CrossRef41
Rajmohan Murali, Lauren E. Haydu, Michael J. Quinn, Robyn P. M. Saw, Kerwin Shannon, Andrew J. Spillane, Jonathan R. Stretch, John F. Thompson, Richard A. Scolyer. (2011) Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery1
CrossRef42
Milap G. Rughani, Marc C. Swan, Titus S. Adams, Mark R. Middleton, Roger N. Ramcharan, Andy Pay, Jeremy F. Birch, David J. Coleman, Oliver C. Cassell. (2011) Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience. Journal of Plastic, Reconstructive & Aesthetic Surgery 64:10, 1284-1290
CrossRef43
Rikke Riber-Hansen, Nina Hastrup, Ole Clemmensen, Nille Behrendt, Siri Klausen, Mette Ramsing, Eva Spaun, Stephen Jacques Hamilton-Dutoit, Torben Steiniche. (2011) Treatment influencing down-staging in EORTC Melanoma Group sentinel node histological protocol compared with complete step-sectioning: A national multicentre study. European Journal of Cancer
CrossRef44
C. A. Voit, A. C. J. van Akkooi, A. M. M. Eggermont, G. Schafer-Hesterberg, M. Kron, J. Ulrich, W. Sterry, A. Schoengen, J. Rademaker. (2011) Fine Needle Aspiration Cytology of Palpable and Nonpalpable Lymph Nodes to Detect Metastatic Melanoma. JNCI Journal of the National Cancer Institute
CrossRef45
Lutz Kretschmer, Hans Starz, Kai-Martin Thoms, Imke Satzger, Bernward Völker, Klaus Jung, Christina Mitteldorf, Claudia Bader, Katharina Siedlecki, Alexander Kapp, Hans Peter Bertsch, Ralf Gutzmer. (2011) Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. International Journal of Cancer 129:6, 1435-1442
CrossRef46
Duan-Ren Wen, Alistair J. Cochran, Rong-Rong Huang, Eijun Itakura, Scott Binder. (2011) Clinically relevant information from sentinel lymph node biopsies of melanoma patients. Journal of Surgical Oncology 104:4, 369-378
CrossRef47
Ryan C. Fields, Klaus J. Busam, Joanne F. Chou, Katherine S. Panageas, Melissa P. Pulitzer, Dennis H. Kraus, Mary S. Brady, Daniel G. Coit. (2011) Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. Annals of Surgical Oncology 18:9, 2529-2537
CrossRef48
A. Clemente-Ruiz de Almiron, S. Serrano-Ortega. (2011) Factores de riesgo de metástasis en tránsito en pacientes con melanoma cutáneo. Actas Dermo-Sifiliográficas
CrossRef49
Elisabeth Livingstone, Christine Windemuth-Kieselbach, Thomas K. Eigentler, Rainer Rompel, Uwe Trefzer, Dorothee Nashan, Sebastian Rotterdam, Selma Ugurel, Dirk Schadendorf. (2011) A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. European Journal of Cancer 47:13, 1977-1989
CrossRef50
S. Lourari, C. Paul, P.-A. Gouraud, S. Tavitian, R. Viraben, M.-T. Leccia, P. Saiag, C. Lebbe, N. Meyer, . (2011) Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef51
Waddah B. Al-Refaie, Selwyn M. Vickers, Wei Zhong, Helen Parsons, David Rothenberger, Elizabeth B. Habermann. (2011) Cancer Trials Versus the Real World in the United States. Annals of Surgery 254:3, 438-443
CrossRef52
Kenjiro NAMIKAWA, Naoya YAMAZAKI, Yasuo NAKAI, Hironobu IHN, Yasushi TOMITA, Hisashi UHARA, Tatsuya TAKENOUCHI, Yoshio KIYOHARA, Yoichi MOROI, Yuhei YAMAMOTO, Fujio OTSUKA, Hideki KAMIYA, Hajime IIZUKA, Naohito HATTA, Takafumi KADONO. (2011) Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: A multi-institutional study of 450 patients in Japan. The Journal of Dermatologyno-no
CrossRef53
Mark B. Faries, Donald L. Morton, Alistair J. Cochran, John F. Thompson. (2011) Reply to Letter to the Editor “Lymphoedema in the Observation and Biopsy Arms of MSLT-1” by Thomas, J Meirion (ASO-2011-04-0666). Annals of Surgical Oncology
CrossRef54
(2011) Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. New England Journal of Medicine 365:6, 569-571
Full Text55
S. Pasquali, S. Mocellin, L.G. Campana, A. Vecchiato, E. Bonandini, M.C. Montesco, S. Santarcangelo, G. Zavagno, D. Nitti, C.R. Rossi. (2011) Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma. European Journal of Surgical Oncology (EJSO) 37:8, 675-680
CrossRef56
Li-Te Lin, Chung-Bin Liu, San-Nung Chen, An-Jen Chiang, Wen-Shiung Liou, Ken-Jen Yu. (2011) Primary malignant melanoma of the vagina with repeated local recurrences and brain metastasis. Journal of the Chinese Medical Association 74:8, 376-379
CrossRef57
Nicholas C. Lee, Andrew J. Spillane, Tony C. Y. Pang, Lauren E. Haydu, Roger F. Uren. (2011) Incomplete Sentinel Node Biopsy Is Not Clearly Related to Survival or Regional Recurrence in Cutaneous Melanoma Patients. Annals of Surgical Oncology
CrossRef58
Kohichi Yamauchi, Hiroshi Nagafuji, Takehiro Nakamura, Takayuki Sato, Naoyuki Kohno. (2011) Feasibility of ICG Fluorescence-Guided Sentinel Node Biopsy in animal Models using the HyperEye Medical System. Annals of Surgical Oncology 18:7, 2042-2047
CrossRef59
Shawn T. Steen, Hamed Kargozaran, Christopher J. Moran, Myung Shin-Sim, Donald L. Morton, Mark B. Faries. (2011) Management of Popliteal Sentinel Nodes in Melanoma. Journal of the American College of Surgeons 213:1, 180-186
CrossRef60
Mark B. Faries, Stephan Ariyan. (2011) Current Surgical Treatment in Melanoma. Current Problems in Cancer 35:4, 173-184
CrossRef61
Steve R. Martinez, Warren H. Tseng, Shawn E. Young. (2011) Outcomes for Lymph Node-Positive Cutaneous Melanoma Over Two Decades. World Journal of Surgery 35:7, 1567-1572
CrossRef62
Julia A. Newton Bishop. 2011. Melanocytic Naevi and Melanoma. , 109.1-109.28.
CrossRef63
Rajmohan Murali, Chitra Desilva, John F. Thompson, Richard A. Scolyer. (2011) Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery 253:6, 1155-1164
CrossRef64
T. Wagner, N. Meyer, S. Zerdoud, A. Julian, C. Chevreau, P. Payoux, F. Courbon. (2011) Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. British Journal of Dermatology 164:6, 1235-1240
CrossRef65
C. Biver-Dalle, E. Puzenat, M.P. Algros, D. Delroeux, H. Bouladhour, F. Pelletier, M.O. Rioux-Gotta, S. Penz, C. Saccomani, S. Cunat-Peultier, P. Humbert, F. Aubin. (2011) P023. Sentinel lymph node biopsy for melanoma. Melanoma Research 21, e29
CrossRef66
Konstantinos Linos, Andrzej Slominski, Jeffrey S Ross, J Andrew Carlson. (2011) Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. Biomarkers in Medicine 5:3, 333-360
CrossRef67
Jonathan P. Sleeman, Irina Nazarenko, Wilko Thiele. (2011) Do all roads lead to Rome? Routes to metastasis development. International Journal of Cancer 128:11, 2511-2526
CrossRef68
Ines Buccimazza. (2011) Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities. World Journal of Surgery 35:6, 1155-1158
CrossRef69
Gershenwald, Jeffrey E., Ross, Merrick I., . (2011) Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. New England Journal of Medicine 364:18, 1738-1745
Full Text70
Henry C Kitchener. (2011) Sentinel-node biopsy in endometrial cancer: a win–win scenario?. The Lancet Oncology 12:5, 413-414
CrossRef71
Adriano Piris, Martin C. Mihm, Lyn M. Duncan. (2011) AJCC melanoma staging update: impact on dermatopathology practice and patient management. Journal of Cutaneous Pathology 38:5, 394-400
CrossRef72
Stanley P.L. Leong, Jeffrey E. Gershenwald, Seng-jaw Soong, Dirk Schadendorf, Ahmad A. Tarhini, Sanjiv Agarwala, Axel Hauschild, Christopher W.M. Soon, Adil Daud, Mohammed Kashani-Sabet. (2011) Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology 103:6, 538-549
CrossRef73
Lutz Kretschmer. (2011) Comments and Notes. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:5, 431-431
CrossRef74
F Rondelli, MC Vedovati, C Becattini, GM Tomassini, S Messina, G Noya, S Simonetti, P Covarelli. (2011) Prognostic role of sentinel node biopsy in patients with thick melanoma: a meta-analysis. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef75
Stanley P.L. Leong, Markus Zuber, Robert L. Ferris, Yuko Kitagawa, Ramon Cabanas, Charles Levenback, Mark Faries, Sukamal Saha. (2011) Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients. Journal of Surgical Oncology 103:6, 518-530
CrossRef76
Vincenzo De Giorgi, Andrea Saggini, Marta Grazzini, Alessia Gori, Susanna Rossari, Federica Scarfì, Alice Verdelli, Sergio Chimenti, Torello Lotti, Daniela Massi. (2011) Specific challenges in the management of subungual melanoma. Expert Review of Anticancer Therapy 11:5, 749-761
CrossRef77
Elena Gallego, Luis Vicioso, Martina Álvarez, Isabel Hierro, Lidia Pérez-Villa, Alfredo Blanes, Alfredo Matilla. (2011) Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas. Virchows Archiv 458:5, 621-630
CrossRef78
Anthony J. Chambers, Tania Murynka, John P. Arlette, J. Gregory Mckinnon. (2011) Invasive melanoma of the face: Management, outcomes, and the role of sentinel lymph node biopsy in 260 patients at a single institution. Journal of Surgical Oncology 103:5, 426-430
CrossRef79
Daniel E. Martin, Joseph C. English, Robert J. Goitz. (2011) Subungual Malignant Melanoma. The Journal of Hand Surgery 36:4, 704-707
CrossRef80
Christian Kunte, Till Geimer, Jens Baumert, Birger Konz, Matthias Volkenandt, Michael Flaig, Thomas Ruzicka, Carola Berking, Monika-H. Schmid-Wendtner. (2011) Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. Journal of the American Academy of Dermatology 64:4, 655-662
CrossRef81
Stanley P. L. Leong, Julian Kim, Merrick Ross, Mark Faries, Charles R. Scoggins, Wendy L. Rich Metz, Frederick O. Cope, Richard C. Orahood. (2011) A Phase 2 Study of 99mTc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer. Annals of Surgical Oncology 18:4, 961-969
CrossRef82
Andrew John Spillane, Monica Tucker, Sandro Pasquali. (2011) A Pilot Study Reporting Outcomes for Melanoma Patients of a Minimal Access Ilio-inguinal Dissection Technique Based on Two Incisions. Annals of Surgical Oncology 18:4, 970-976
CrossRef83
Peter Brader, Richard J. Wong, Gilad Horowitz, Ziv Gil. (2011) Combination of pet imaging with viral vectors for identification of cancer metastases. Advanced Drug Delivery Reviews
CrossRef84
Lily L. Altstein, Gang Li, Robert M. Elashoff. (2011) A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial. Statistics in Medicine 30:7, 709-717
CrossRef85
2011. Neoplasms. , 118-204.
CrossRef86
Carol Calianno. (2011) Influencing melanoma prevention. The Nurse Practitioner 36:3, 6-10
CrossRef87
I Stoffels, T Poeppel, C Boy, S Mueller, F Wichmann, J Dissemond, D Schadendorf, S Rosenbaum-Krumme, J Klode. (2011) Radio-guided surgery: advantages of a new portable γ-camera (Sentinella®) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef88
I Stoffels, J Dissemond, A Körber, U Hillen, T Poeppel, D Schadendorf, J Klode. (2011) Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II. Journal of the European Academy of Dermatology and Venereology 25:3, 306-310
CrossRef89
I Stoffels, J Dissemond, T Poeppel, K Klötgen, U Hillen, A Körber, D Schadendorf, J Klode. (2011) Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef90
Gasper Pilko, Nikola Besic, Janez Zgajnar, Marko Hocevar. (2011) Prognostic heterogeneity after the excision of lymph node metastases in patients with cutaneous melanoma. Surgical Oncology 20:1, 26-34
CrossRef91
S. Kruijff, E. Bastiaannet, M.J. Speijers, A.C.M. Kobold, A.H. Brouwers, H.J. Hoekstra. (2011) The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. European Journal of Surgical Oncology (EJSO) 37:3, 225-232
CrossRef92
I Stoffels, J Dissemond, A Schulz, U Hillen, D Schadendorf, J Klode. (2011) Reliability and cost-effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia: a retrospective analysis in patients with malignant melanoma AJCC stage III. Journal of the European Academy of Dermatology and Venereologyno-no
CrossRef93
I. Satzger, A. Meier, L. Hoy, B. Völker, A. Kapp, A. Hauschild, R. Gutzmer. (2011) Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up. Annals of Surgical Oncology 18:2, 514-520
CrossRef94
FLORENT GRANGE, EVE MAUBEC, CORALIE BARBE, JAMAL KASSOUMA, FABIEN VITRY, HUBERT JOHANET, FLORENCE GRANEL-BROCARD, FRANCOISE BOITIER, ANGELIQUE GIROD, BENOIT COUTURAUD, PIERRE SAEZ, SEBASTIEN ALBERT, ANNICK LE CLAINCHE, VINCENT DESCAMPS, MARIE FRANCOISE AVRIL. (2011) Sentinel Lymph Node Biopsy or Nodal Observation in Melanoma: A Prospective Study of Patient Choices. Dermatologic Surgery 37:2, 199-206
CrossRef95
Ulrike Leiter, Claus Garbe. (2011) In Reply: Sentinel Lymph Node Biopsy in Melanoma. Annals of Surgical Oncology 18:2, 598-599
CrossRef96
Vincenzo Giorgi, Marta Grazzini, Federica Papi, Alessia Gori, Susanna Rossari, Torello Lotti. (2011) Sentinel Lymph Node Biopsy: Is It an Evolution of the Management of Cutaneous Melanoma?. Annals of Surgical Oncology 18:2, 597-597
CrossRef97
Glenda G. Callender, Kelly M. McMasters. (2011) Early versus Delayed Complete Lymphadenectomy in Melanoma: Insight from MSLT I. Annals of Surgical Oncology 18:2, 306-308
CrossRef98
Lutz Kretschmer, Carsten Oliver Sahlmann, Pawel Bardzik, Kai-Martin Thoms, Hans Peter Bertsch, Johannes Meller. (2011) The popliteal fossa - a problem zone for sentinel lymphonodectomy. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9:2, 123-127
CrossRef99
Ophelia E Dadzie, Michael Neat, Andrew Emley, Jag Bhawan, Meera Mahalingam. (2011) Molecular Diagnostics—An Emerging Frontier in Dermatopathology. The American Journal of Dermatopathology 33:1, 1-16
CrossRef100
Euphemia Mu, Julie R. Lange, John J. Strouse. (2011) Comparison of the use and results of sentinel lymph node biopsy in children and young adults with melanoma. Cancern/a-n/a
CrossRef101
Christoforos Kosmidis, Christoforos Efthimiadis, Georgios Anthimidis, Marios Grigoriou, Kalliopi Vasiliadou, Georgia Ioannidou, Fotini Makedou, Sofia Baka. (2011) Acral Lentiginous Melanoma: A Case Control Study and Guidelines Update. Case Reports in Medicine 2011, 1-4
CrossRef102
Anne C. van Leeuwen, Tessa Buckle, Gavin Bendle, Lenka Vermeeren, Renato Valdés Olmos, Henk G. van de Poel, Fijs W. B. van Leeuwen. (2011) Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. Journal of Biomedical Optics 16:1, 016004
CrossRef103
Giorgos C. Karakousis, Brian J. Czerniecki. (2011) Diagnosis of Melanoma. PET Clinics 6:1, 1-8
CrossRef104
Ari-Nareg Meguerditchian, Kobby Asubonteng, Calvin Young, Bethany Lema, Gregory Wilding, John M Kane III. (2011) Thick primary melanoma has a heterogeneous tumor biology: an institutional series. World Journal of Surgical Oncology 9:1, 40
CrossRef105
Lenka Vermeeren, Renato A. Valdés Olmos, W. Martin C. Klop, Iris M. C. van der Ploeg, Omgo E. Nieweg, Alfons J. M. Balm, Michiel W. M. van den Brekel. (2011) SPECT/CT for sentinel lymph node mapping in head and neck melanoma. Head & Neck 33:1, 1-6
CrossRef106
Michael B. Nicholl, David Elashoff, Hiroya Takeuchi, Donald L. Morton, Dave S. B. Hoon. (2011) Molecular Upstaging Based on Paraffin-Embedded Sentinel Lymph Nodes. Annals of Surgery 253:1, 116-122
CrossRef107
Thomas J. Ow, Jeffrey N. Myers. (2011) Current Management of Advanced Resectable Oral Cavity Squamous Cell Carcinoma. Clinical and Experimental Otorhinolaryngology 4:1, 1
CrossRef108
Steve Kwon, Zhao Dong, Peter C Wu. (2011) Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World Journal of Surgical Oncology 9:1, 80
CrossRef109
Elif Hindié, Farid Sarandi, Soraya Banayan, David Groheux, Domenico Rubello, Laetitia Vercellino, Marie-Elisabeth Toubert, Jean-Luc Moretti, Céleste Lebbé. (2011) Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy—FDG-PET/CT. PET Clinics 6:1, 9-25
CrossRef110
A. M. Manganoni, R. Farfaglia, E. Sereni, C. Farisoglio, C. Pizzocaro, D. Marocolo, F. Gavazzoni, L. Pavoni, P. Calzavara-Pinton. (2011) Interval Sentinel Lymph Nodes: An Unusual Localization in Patients with Cutaneous Melanoma. Dermatology Research and Practice 2011, 1-3
CrossRef111
Yuan Wang, Thomas J. Ow, Jeffrey N. Myers. (2011) Pathways for cervical metastasis in malignant neoplasms of the head and neck region. Clinical Anatomyn/a-n/a
CrossRef112
Jithin Jose, Diederik J. Grootendorst, Thomas W. Vijn, Michel W. Wouters, Hester van Boven, Ton G. van Leeuwen, Wiendelt Steenbergen, Theo J. M. Ruers, Srirang Manohar. (2011) Initial results of imaging melanoma metastasis in resected human lymph nodes using photoacoustic computed tomography. Journal of Biomedical Optics 16:9, 096021
CrossRef113
Aaron Savar, Patrick Oellers, Jeffrey Myers, Victor G. Prieto, Carlos Torres-Cabala, Steven J. Frank, Doina Ivan, Bita Esmaeli. (2011) Positive Sentinel Node in Sebaceous Carcinoma of the Eyelid. Ophthalmic Plastic & Reconstructive Surgery 27:1, e4-e6
CrossRef114
James J. Jaber, Joseph I. Clark, Kamil Muzaffar, Francis P. Ruggiero, Paul J. Feustel, Michael J. Frett, Chad A. Zender. (2011) Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience. Head & Neck 33:1, 7-12
CrossRef115
Takashi Matsuzuka, Tomohiro Miura, Masahiro Suzuki, Shuji Yokoyama, Takamichi Matsui, Yukio Nomoto, Miha Kunii, Satoshi Saijoh, Koich Omori. (2011) Sentinel node biopsy for deciding neck dissection for early-stage tongue cancer. Toukeibu Gan 37:3, 355-358
CrossRef116
Jukes P. Namm, Alfred E. Chang, Vincent M. Cimmino, Riley S. Rees, Timothy M. Johnson, Michael S. Sabel. (2011) Is a level III dissection necessary for a positive sentinel lymph node in melanoma?. Journal of Surgical Oncologyn/a-n/a
CrossRef117
Audrey B. Erman, Ryan M. Collar, Kent A. Griffith, Lori Lowe, Michael S. Sabel, Christopher K. Bichakjian, Sandra L. Wong, Scott A. McLean, Riley S. Rees, Timothy M. Johnson, Carol R. Bradford. (2011) Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancern/a-n/a
CrossRef118
Kerry L. Hollowell, Steven C. Agle, Emmanuel E. Zervos, Timothy L. Fitzgerald. (2011) Cutaneous apocrine adenocarcinoma: Defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. Journal of Surgical Oncologyn/a-n/a
CrossRef119
J. Wisell. (2011) Outcome of Patients with a Positive Sentinel Lymph Node who do not Undergo Completion Lymphadenectomy. Yearbook of Pathology and Laboratory Medicine 2011, 58-59
CrossRef120
Tessa Buckle, Patrick T K Chin, Fijs W B van Leeuwen. (2010) (Non-targeted) radioactive/fluorescent nanoparticles and their potential in combined pre- and intraoperative imaging during sentinel lymph node resection. Nanotechnology 21:48, 482001
CrossRef121
Benjamin E. Saltman, Ian Ganly, Snehal G. Patel, Daniel G. Coit, Mary Sue Brady, Richard J. Wong, Jay O. Boyle, Bhuvanesh Singh, Ashok R. Shaha, Jatin P. Shah, Dennis H. Kraus. (2010) Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head & Neck 32:12, 1686-1692
CrossRef122
Piotr Rutkowski, Zbigniew I. Nowecki, Alexander C. J. Akkooi, Jadwiga Kulik, Michej Wanda, Janusz A. Siedlecki, Alexander M. M. Eggermont, Wlodzimierz Ruka. (2010) Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden. Annals of Surgical Oncology 17:12, 3314-3323
CrossRef123
Daryl Godden, Peter A. Brennan, James Milne. (2010) Update on melanoma: the present position. British Journal of Oral and Maxillofacial Surgery 48:8, 575-578
CrossRef124
Dieter Hölzel, Renate Eckel, Rebecca T. Emeny, Jutta Engel. (2010) Distant metastases do not metastasize. Cancer and Metastasis Reviews 29:4, 737-750
CrossRef125
Russell E. Brown, Merrick I. Ross, Michael J. Edwards, R. Dirk Noyes, Douglas S. Reintgen, Lee J. Hagendoorn, Arnold J. Stromberg, Robert C. G. Martin, Kelly M. McMasters, Charles R. Scoggins. (2010) The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma. Annals of Surgical Oncology 17:12, 3330-3335
CrossRef126
Amy Frankenthaler, Ryan J. Sullivan, Wei Wang, Sharon Renzi, Virginia Seery, Mee-Young Lee, Michael B. Atkins. (2010) Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. Melanoma Research 20:6, 496-500
CrossRef127
, Mark B. Faries, John F. Thompson, Alistair Cochran, Robert Elashoff, Edwin C. Glass, Nicola Mozzillo, Omgo E. Nieweg, Daniel F. Roses, Harold J. Hoekstra, Constantine P. Karakousis, Douglas S. Reintgen, Brendon J. Coventry, He-Jing Wang, Donald L. Morton. (2010) The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). Annals of Surgical Oncology 17:12, 3324-3329
CrossRef128
Merrick I. Ross. (2010) Sentinel Node Biopsy for Melanoma: An Update After Two Decades of Experience. Seminars in Cutaneous Medicine and Surgery 29:4, 238-248
CrossRef129
Michael Frumovitz, Mariano Etchepareborda, Charlotte C. Sun, Pamela T. Soliman, Patricia J. Eifel, Charles F. Levenback, Pedro T. Ramirez. (2010) Primary Malignant Melanoma of the Vagina. Obstetrics & Gynecology 116:6, 1358-1365
CrossRef130
I. Satzger, M. Klein, C. Löser, S. Reske, A. Kapp, R. Gutzmer. (2010) Schildwächterlymphknotenbiopsie beim Melanom. Der Onkologe 16:12, 1140-1149
CrossRef131
Mehul V. Raval, Karl Y. Bilimoria, David J. Bentrem, Andrew K. Stewart, Clifford Y. Ko, Marleta Reynolds, Jeffrey D. Wayne. (2010) Use of sentinel lymph node biopsy for melanoma in children and adolescents. Journal of Surgical Oncology 102:6, 634-639
CrossRef132
Ali Cadili, Richard A. Scolyer, Philip T. Brown, Kelly Dabbs, John F. Thompson. (2010) Total Sentinel Lymph Node Tumor Size Predicts Nonsentinel Node Metastasis and Survival in Patients with Melanoma. Annals of Surgical Oncology 17:11, 3015-3020
CrossRef133
Raquel Sanchez, Doina Ivan, Bita Esmaeli. (2010) Eyelid and Periorbital Cutaneous Malignant Melanoma. International Ophthalmology Clinics 49:4, 25-43
CrossRef134
A Mitra, C Conway, C Walker, M Cook, B Powell, S Lobo, M Chan, M Kissin, G Layer, J Smallwood, C Ottensmeier, P Stanley, H Peach, H Chong, F Elliott, M M Iles, J Nsengimana, J H Barrett, D T Bishop, J A Newton-Bishop. (2010) Melanoma sentinel node biopsy and prediction models for relapse and overall survival. British Journal of Cancer 103:8, 1229-1236
CrossRef135
Amanda Silverio, Matthew McRae, Stephan Ariyan, Deepak Narayan. (2010) Management of the Difficult Sentinel Lymph Node in Patients With Primary Cutaneous Melanoma. Annals of Plastic Surgery 65:4, 418-424
CrossRef136
VINCENZO PANASITI, VALERIA DEVIRGILIIS, MICHELA CURZIO, VINCENZO ROBERTI, SILVIA GOBBI, MARIARITA ROSSI, UGO BOTTONI, RITA CLERICO, NICOLO SCUDERI, STEFANO CALVIERI. (2010) Predictive Factors for False Negative Sentinel Lymph Node in Melanoma Patients. Dermatologic Surgery 36:10, 1521-1528
CrossRef137
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Tsao, Hensin, Tanabe, Kenneth K., Lawrence, Donald P., Piris, Adriano, . (2010) Case 30-2010. New England Journal of Medicine 363:14, 1352-1360
Full Text138
Carrie K. Chu, Jonathan S. Zager, Suroosh S. Marzban, Mark I. Gimbel, Douglas R. Murray, Andrea C. Hestley, Jane L. Messina, Vernon K. Sondak, Grant W. Carlson, Keith A. Delman. (2010) Routine biopsy of cloquet's node is of limited value in sentinel node positive melanoma patients. Journal of Surgical Oncology 102:4, 315-320
CrossRef139
Kenneth H. Kim, David M. O'Malley, Jeffrey M. Fowler. 2010. Cancer in the Pregnant Patient. , 704-716.
CrossRef140
Augustinus P.T. van der Ploeg, Alexander C.J. van Akkooi, Paul I.M. Schmitz, Senada Koljenovic, Cornelis Verhoef, Alexander M.M. Eggermont. (2010) EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. European Journal of Cancer 46:13, 2414-2421
CrossRef141
Yevgeniy Shildkrot, Matthew W Wilson. (2010) Conjunctival melanoma: pitfalls and dilemmas in management. Current Opinion in Ophthalmology 21:5, 380-386
CrossRef142
J.R. Marsden, J.A. Newton-Bishop, L. Burrows, M. Cook, P.G. Corrie, N.H. Cox, M.E. Gore, P. Lorigan, R. MacKie, P. Nathan, H. Peach, B. Powell, C. Walker. (2010) Revised UK guidelines for the management of cutaneous melanoma 2010. Journal of Plastic, Reconstructive & Aesthetic Surgery 63:9, 1401-1419
CrossRef143
Rajmohan Murali, Helen M. Shaw, Kenneth Lai, Stanley W. McCarthy, Michael J. Quinn, Jonathan R. Stretch, John F. Thompson, Richard A. Scolyer. (2010) Prognostic factors in cutaneous desmoplastic melanoma. Cancer 116:17, 4130-4138
CrossRef144
Maaike HM Oonk, Joanne A de Hullu, Ate GJ van der Zee. (2010) Current controversies in the management of patients with early-stage vulvar cancer. Current Opinion in Oncology 22:5, 481-486
CrossRef145
Alexander C. J. van Akkooi, Cornelis Verhoef, Alexander M. M. Eggermont. (2010) Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nature Reviews Clinical Oncology 7:8, 446-454
CrossRef146
E. Richtig, P. Komericki, M. Trapp, A. Ott, B. Bisail, J.W. Egger, I. Zalaudek. (2010) Ratio of marked and excised sentinel lymph nodes and scintigraphic appearance time in melanoma patients with negative sentinel lymph node. European Journal of Surgical Oncology (EJSO) 36:8, 783-788
CrossRef147
J.R. Marsden, J.A. Newton-Bishop, L. Burrows, M. Cook, P.G. Corrie, N.H. Cox, M.E. Gore, P. Lorigan, R. MacKie, P. Nathan, H. Peach, B. Powell, C. Walker. (2010) Revised U.K. guidelines for the management of cutaneous melanoma 2010. British Journal of Dermatology 163:2, 238-256
CrossRef148
Martin Wiener, Katharine M. Acland, Helen M. Shaw, Seng-Jaw Soong, Hui-Yi Lin, Dung-Tsa Chen, Richard A. Scolyer, Julie B. Winstanley, John F. Thompson. (2010) Sentinel Node Positive Melanoma Patients: Prediction and Prognostic Significance of Nonsentinel Node Metastases and Development of a Survival Tree Model. Annals of Surgical Oncology 17:8, 1995-2005
CrossRef149
Maarten J Speijers, Anne Brecht Francken, Josette EHM Hoekstra-Weebers, Esther Bastiaannet, Schelto Kruijff, Harald J Hoekstra. (2010) Optimal follow-up for melanoma. Expert Review of Dermatology 5:4, 461-478
CrossRef150
Gino R. Somers, Susan Chilton-MacNeill, Keqin Zheng, Mary Stuart, Alberto Pappo, Maria Zielenska, Paul S. Thorner. (2010) Increased Detection of Metastatic Melanoma in Pediatric Sentinel Lymph Node Biopsies Using RT-PCR on Paraffin-embedded Tissue. Applied Immunohistochemistry & Molecular Morphology 18:4, 365-370
CrossRef151
Sanjay P. Bagaria, Mark B. Faries, Donald L. Morton. (2010) Sentinel node biopsy in melanoma: Technical considerations of the procedure as performed at the john wayne cancer institute. Journal of Surgical Oncology 101:8, 669-676
CrossRef152
Bao Lam, Patrick A Ott, Anna C Pavlick. (2010) Cutaneous melanoma in the elderly: epidemiology and management. Aging Health 6:3, 383-392
CrossRef153
Rajmohan Murali, John F. Thompson, Richard A. Scolyer. (2010) Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery 251:6, 1188-1189
CrossRef154
L. Tomás-Mallebrera, R. Rojo-España, A. Marquina-Vila, N. Gimeno-Clemente, M.M. Morales-Suárez-Varela. (2010) La técnica del ganglio centinela en pacientes con melanoma. Actas Dermo-Sifiliográficas 101:5, 428-436
CrossRef155
Ettore Minutilli. (2010) New research advances for treating metastatic melanoma. International Journal of Dermatology 49:6, 712-714
CrossRef156
Natasha M. Rueth, Shawn S. Groth, Todd M. Tuttle, Beth A. Virnig, Waddah B. Al-Refaie, Elizabeth B. Habermann. (2010) Conditional Survival After Surgical Treatment of Melanoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Annals of Surgical Oncology 17:6, 1662-1668
CrossRef157
William G. Stebbins, Lilit Garibyan, Arthur J. Sober. (2010) Sentinel lymph node biopsy and melanoma: 2010 update. Journal of the American Academy of Dermatology 62:5, 737-748
CrossRef158
Heather M. Richmond, Madeleine Duvic, Deborah F. MacFarlane. (2010) Primary and Metastatic Malignant Tumors of the Scalp. American Journal of Clinical Dermatology1
CrossRef159
Raymond L. Warters, Pamela B. Cassidy, Jeremy A. Sunseri, Krishna Parsawar, Sergey B. Zhuplatov, Gwen F. Kramer, Sancy A. Leachman. (2010) The nuclear matrix shell proteome of human epidermis. Journal of Dermatological Science 58:2, 113-122
CrossRef160
Alexander CJ van Akkooi, Christiane A Voit, Cornelis Verhoef, Alexander MM Eggermont. (2010) New developments in sentinel node staging in melanoma: controversies and alternatives. Current Opinion in Oncology 22:3, 169-177
CrossRef161
R. Dummer, A. Hauschild, M. Guggenheim, L. Jost, G. Pentheroudakis, . (2010) Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v194-v197
CrossRef162
Brooke T. Baldwin, Basil S. Cherpelis, Vernon Sondak, Neil Alan Fenske. (2010) Sentinel lymph node biopsy in melanoma: Facts and controversies. Clinics in Dermatology 28:3, 319-323
CrossRef163
Michelle C. Ellis, Roshanthi Weerasinghe, Christopher L. Corless, John T. Vetto. (2010) Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. The American Journal of Surgery 199:5, 663-668
CrossRef164
F. O. Zwald, L. J. Christenson, E. M. Billingsley, N. C. Zeitouni, D. Ratner, J. Bordeaux, M. J. Patel, M. D. Brown, C. M. Proby, S. Euvrard, C. C. Otley, T. Stasko, . (2010) Melanoma in Solid Organ Transplant Recipients. American Journal of Transplantation 10:5, 1297-1304
CrossRef165
G. Pentheroudakis, R. Orecchia, H. J. Hoekstra, N. Pavlidis, . (2010) Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v266-v273
CrossRef166
Matthew H. Kanzler. (2010) Sentinel node biopsy and standard of care for melanoma: A re-evaluation of the evidence. Journal of the American Academy of Dermatology 62:5, 880-884
CrossRef167
Christopher K. Bichakjian, Daniel G. Coit, Sandra L. Wong. (2010) Radiation versus resection for Merkel cell carcinoma. Cancer 116:7, 1620-1622
CrossRef168
Frederico Teixeira, Eduardo Akaishi, Gabriella Mendes, Vitor Moutinho, Edivaldo Utiyama, Samir Rasslan. (2010) Mid-humeral sentinel lymph node dissection in patients with primary cutaneous malignant melanoma. Melanoma Research 20:2, 138-140
CrossRef169
Michael J. Sladden, Peter Foley, Duncan G. Stanford, Samuel Zagarella, Catherine Reid. (2010) Sentinel node biopsy: Not the standard of care for melanoma. Journal of the American Academy of Dermatology 62:4, 708-709
CrossRef170
Rajmohan Murali, John F Thompson, Roger F Uren, Richard A Scolyer. (2010) Fine-needle biopsy of metastatic melanoma: clinical use and new applications. The Lancet Oncology 11:4, 391-400
CrossRef171
Javier Soteldo, Enrico Luigi Ratto, Sara Gandini, Giuseppe Trifirò, Giovanni Mazzarol, Giulio Tosti, Marco Rastrelli, Francesco Verrecchia, Federica Baldini, Alessandro Testori. (2010) Pelvic sentinel lymph node biopsy in melanoma patients: is it worthwhile?. Melanoma Research 20:2, 133-137
CrossRef172
Thiago Francischetto, Nelson Spector, Jose Francisco Neto Rezende, Marcelle Azevedo Antunes, Sergio Oliveira Romano, Isabele A. Small, Carlos Gil Ferreira. (2010) Influence of Sentinel Lymph Node Tumor Burden on Survival in Melanoma. Annals of Surgical Oncology 17:4, 1152-1158
CrossRef173
JOACHIM KLODE, JOACHIM DISSEMOND, STEPHAN GRABBE, UWE HILLEN, THORSTEN POEPPEL, CARSTEN BOEING. (2010) Sentinel Lymph Node Excision and PET-CT in the Initial Stage of Malignant Melanoma: A Retrospective Analysis of 61 Patients with Malignant Melanoma in American Joint Committee on Cancer Stages I and II. Dermatologic Surgery 36:4, 439-445
CrossRef174
Y. Socrier, V. Lauwers-Cances, L. Lamant, I. Garrido, F. Lauwers, R. Lopez, P. Rochaix, C. Chevreau, P. Payoux, R. Viraben, C. Paul, N. Meyer. (2010) Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. British Journal of Dermatology 162:4, 830-834
CrossRef175
J. A. Newton Bishop. 2010. Lentigos, Melanocytic Naevi and Melanoma. , 1-57.
CrossRef176
Michael P. Mays, Robert C. G. Martin, Alison Burton, Brooke Ginter, Michael J. Edwards, Douglas S. Reintgen, Merrick I. Ross, Marshall M. Urist, Arnold J. Stromberg, Kelly M. McMasters, Charles R. Scoggins. (2010) Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?. Cancer 116:6, 1535-1544
CrossRef177
Jane L. Messina, Vernon K. Sondak. (2010) Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma. Cancer 116:6, 1403-1405
CrossRef178
Sandro Pasquali, Simone Mocellin, Luca G. Campana, Elena Bonandini, Maria C. Montesco, Alberto Tregnaghi, Paolo Del Fiore, Donato Nitti, Carlo R. Rossi. (2010) Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases. Cancer 116:5, 1201-1209
CrossRef179
Vernon K. Sondak, Jonathan S. Zager. (2010) Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?. Annals of Surgical Oncology 17:3, 670-673
CrossRef180
David R. Byrd. (2010) The persistent anchor of lymph node removal in patients with melanoma. Cancer 116:5, 1150-1152
CrossRef181
Charles R. Scoggins, Robert C. G. Martin, Merrick I. Ross, Michael J. Edwards, Douglas S. Reintgen, Marshall M. Urist, Jeffrey E. Gershenwald, Jeffrey J. Sussman, R. Dirk Noyes, James S. Goydos, Peter D. Beitsch, Stephan Ariyan, Arnold J. Stromberg, Lee J. Hagendoorn, Kelly M. McMasters. (2010) Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients. Annals of Surgical Oncology 17:3, 709-717
CrossRef182
C. Mangas, C. Paradelo, S. Puig, F. Gallardo, J. Marcoval, A. Azon, R. Bartralot, S. Bel, X. Bigatà, N. Curcó, J. Dalmau, L.J. del Pozo, C. Ferrándiz, M. Formigón, A. González, M. Just, A. Llambrich, E. Llistosella, J. Malvehy, R.M. Martí, M.E. Nogués, R. Pedragosa, V. Rocamora, M. Sàbat, M. Salleras. (2010) Valoración inicial, diagnóstico, estadificación, tratamiento y seguimiento de los pacientes con melanoma maligno primario de la piel. Documento de consenso de la “Xarxa de Centres de Melanoma de Catalunya i Balears”. Actas Dermo-Sifiliográficas 101:2, 129-142
CrossRef183
Susan Tsai, Charles Balch, Julie Lange. (2010) Epidemiology and treatment of melanoma in elderly patients. Nature Reviews Clinical Oncology 7:3, 148-152
CrossRef184
Hidde J. Veenstra, Iris M. C. Ploeg, Michel W. J. M. Wouters, Bin B. R. Kroon, Omgo E. Nieweg. (2010) Reevaluation of the Locoregional Recurrence Rate in Melanoma Patients With a Positive Sentinel Node Compared to Patients With Palpable Nodal Involvement. Annals of Surgical Oncology 17:2, 521-526
CrossRef185
(2010) EDITORIAL. Australasian Journal of Dermatology 51:1, 18-20
CrossRef186
M Lens. (2010) Sentinel lymph node biopsy in melanoma patients. Journal of the European Academy of Dermatology and Venereology
CrossRef187
Alexander C. J. Akkooi, Christiane A. Voit, Cornelis Verhoef, Alexander M. M. Eggermont. (2010) Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up. Annals of Surgical Oncology 17:2, 660-662
CrossRef188
Kelly M. McMasters. (2010) Why Does No One Want to Perform Lymph Node Dissection Anymore?. Annals of Surgical Oncology 17:2, 358-361
CrossRef189
Yasufumi Goto, Takaaki Arigami, Rajmohan Murali, Richard A. Scolyer, Atsushi Tanemura, Minoru Takata, Roderick R. Turner, Linhda Nguyen, Tung Nguyen, Donald L. Morton, Soldano Ferone, Dave S.B. Hoon. (2010) High molecular weightâmelanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell & Melanoma Research 23:1, 137-140
CrossRef190
Christopher Vanison, Neil Tanna, Ananth S. Murthy. (2010) Comparative genomic hybridization for the diagnosis of melanoma. European Journal of Plastic Surgery 33:1, 45-48
CrossRef191
MAJ Scott R. Dalton, Pedram Gerami, Nicholas A. Kolaitis, Susan Charzan, Rob Werling, Philip E. LeBoit, Boris C. Bastian. (2010) Use of Fluorescence In situ Hybridization (FISH) to Distinguish Intranodal Nevus From Metastatic Melanoma. The American Journal of Surgical Pathology 34:2, 231-237
CrossRef192
T. Peter Kingham, Katherine S. Panageas, Charlotte E. Ariyan, Klaus J. Busam, Mary Sue Brady, Daniel G. Coit. (2010) Outcome of Patients with a Positive Sentinel Lymph Node who do not Undergo Completion Lymphadenectomy. Annals of Surgical Oncology 17:2, 514-520
CrossRef193
Sung Mo Hur, Sung Hoon Kim, Se Kyung Lee, Wan Wook Kim, Jae Hyuck Choi, Sangmin Kim, So Young Lim, Jai Kyung Pyon, Goo Hyun Mun, Jun-Ho Choe, Jeong Eon Lee, Jee Soo Kim, Seok-Jin Nam, Jung-Hyun Yang, Jung-Han Kim. (2010) Clinical Usefulness of Sentinel Lymph Node Biopsy in the Surgical Treatment of Malignant Melanoma. Journal of the Korean Surgical Society 79:3, 163
CrossRef194
Vinod B. Shidham. (2010) Evaluation of Sentinel Lymph Nodes for Melanoma Metastases by Pathologists. Clinics in Plastic Surgery 37:1, 101-112
CrossRef195
Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saiag, Mark Middleton, Alain Spatz, Jean-Jacques Grob, Josep Malvehy, Julia Newton-Bishop, Alexander Stratigos, Hubert Pehamberger, Alexander Eggermont. (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European Journal of Cancer 46:2, 270-283
CrossRef196
Maaike HM Oonk, Hedwig P van de Nieuwenhof, Ate GJ van der Zee, Joanne A de Hullu. (2010) Update on the sentinel lymph node procedure in vulvar cancer. Expert Review of Anticancer Therapy 10:1, 61-69
CrossRef197
T. Peter Kingham, Giorgos Karakousis, Charlotte Ariyan. (2010) Randomized Clinical Trials in Melanoma. Surgical Oncology Clinics of North America 19:1, 13-31
CrossRef198
Jeffrey H. Kozlow, Riley S. Rees. (2010) Surgical Management of Primary Disease. Clinics in Plastic Surgery 37:1, 65-71
CrossRef199
Garth S. Herbert, Kevin M. Beshlian. (2010) The Triangular Intermuscular Space as a Site of Lymph Node Metastasis in Melanoma of the Back. Annals of Plastic Surgery 64:1, 52-54
CrossRef200
Yasufumi Goto, Kazuo Koyanagi, Norihiko Narita, Yutaka Kawakami, Minoru Takata, Aya Uchiyama, Linhda Nguyen, Tung Nguyen, Xing Ye, Donald L Morton, Dave S B Hoon. (2010) Aberrant Fatty Acid-Binding Protein-7 Gene Expression in Cutaneous Malignant Melanoma. Journal of Investigative Dermatology 130:1, 221-229
CrossRef201
Ricardo J. Gonzalez, Tapan A. Padhya, Basil S. Cherpelis, Melanie D. Prince, Melanie L. Aya-ay, Vernon K. Sondak, C. Wayne Cruse, Jonathan S. Zager. (2010) The Surgical Management of Primary and Metastatic Merkel Cell Carcinoma. Current Problems in Cancer 34:1, 77-96
CrossRef202
Mark Faries. (2010) Survival and the Sentinel Lymph Node in Melanoma. Annals of Surgical Oncology 17:1, 18-20
CrossRef203
Ulrike Leiter, Petra G. Buettner, Katrin Bohnenberger, Thomas Eigentler, Friedegund Meier, Matthias Moehrle, Helmut Breuninger, Claus Garbe. (2010) Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. Annals of Surgical Oncology 17:1, 129-137
CrossRef204
Robert Howman-Giles, Helen M. Shaw, Richard A. Scolyer, Rajmohan Murali, James Wilmott, Stanley W. McCarthy, Roger F. Uren, John F. Thompson. (2010) Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology 17:1, 138-143
CrossRef205
Friederike Egberts, A. Momkvist, J. H. Egberts, K. C. Kaehler, M. Weichenthal, A. Hauschild. (2010) Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm. Tumor Biology 31:1, 8-15
CrossRef206
M.W. Ludgate, D.R. Fullen, J. Lee, R. Rees, M.S. Sabel, S.L. Wong, T.M. Johnson. (2010) Animal-type melanoma: a clinical and histopathological study of 22 cases from a single institution. British Journal of Dermatology 162:1, 129-136
CrossRef207
DAVID WEEDON, GEOFFREY STRUTTON, ADAM I RUBIN. 2010. Lentigines, nevi, and melanomas. , 709-756.
CrossRef208
2010. 32 Lentigines, nevi, and melanomas. , 617-677.
CrossRef209
Mark J Mentrikoski, Linglei Ma, Jennifer G Pryor, Loralee A McMahon, Qi Yang, Betsy O Spaulding, Glynis A Scott, Hanlin L Wang, Haodong Xu. (2009) Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Modern Pathology 22:12, 1582-1587
CrossRef210
C. Hallermann, J. Atzpodien, M. Klein, A. Krause-Bergmann, G. Brodner, G. Strittmatter, G. Brunner, H.-J. Schulze. (2009) Malignes Melanom. best practice onkologie 4:6, 4-22
CrossRef211
Christina Mitteldorf, Hans P Bertsch, Antonia Zapf, Christine Neumann, Lutz Kretschmer. (2009) Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients. Modern Pathology 22:12, 1622-1627
CrossRef212
Simone Mocellin, John F. Thompson, Sandro Pasquali, Maria C. Montesco, Pierluigi Pilati, Donato Nitti, Robyn P. Saw, Richard A. Scolyer, Jonathan R. Stretch, Carlo R. Rossi. (2009) Sentinel Node Status Prediction by Four Statistical Models. Annals of Surgery 250:6, 964-969
CrossRef213
Stefan S. Kachala, Elliot L. Servais, Bernard J. Park, Valerie W. Rusch, Prasad S. Adusumilli. (2009) Therapeutic Sentinel Lymph Node Imaging. Seminars in Thoracic and Cardiovascular Surgery 21:4, 327-338
CrossRef214
J. Meirion Thomas. (2009) Freedom of expression or protectionism in the debate on sentinel node biopsy in melanoma. Journal of the American Academy of Dermatology 61:6, 1079
CrossRef215
Toshiaki Saida. (2009) Sentinel lymph node biopsy in melanoma management: its significance and potential problems. International Journal of Clinical Oncology 14:6, 483-484
CrossRef216
Hisashi Uhara, Minoru Takata, Toshiaki Saida. (2009) Sentinel lymph node biopsy in Japan. International Journal of Clinical Oncology 14:6, 490-496
CrossRef217
S. Kruijff, E. Bastiaannet, A. C. Muller Kobold, R. J. Ginkel, A. J. H. Suurmeijer, H. J. Hoekstra. (2009) S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients. Annals of Surgical Oncology 16:12, 3455-3462
CrossRef218
Yoichi Moroi. (2009) Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data. International Journal of Clinical Oncology 14:6, 485-489
CrossRef219
Onkar Khullar, John V. Frangioni, Mark Grinstaff, Yolonda Lorig Colson. (2009) Image-Guided Sentinel Lymph Node Mapping and Nanotechnology-Based Nodal Treatment in Lung Cancer Using Invisible Near-Infrared Fluorescent Light. Seminars in Thoracic and Cardiovascular Surgery 21:4, 309-315
CrossRef220
Rajmohan Murali, Alistair J. Cochran, Martin G. Cook, Joseph D. Hillman, Rooshdiya Z. Karim, Marc Moncrieff, Hans Starz, John F. Thompson, Richard A. Scolyer. (2009) Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. Cancer 115:21, 5026-5037
CrossRef221
Hedwig P van de Nieuwenhof, Maaike HM Oonk, Joanne A de Hullu, Ate GJ van der Zee. (2009) Vulvar squamous cell carcinoma. Expert Review of Obstetrics & Gynecology 4:6, 659-672
CrossRef222
Amir A. Ghaferi, Sandra L. Wong, Timothy M. Johnson, Lori Lowe, Alfred E. Chang, Vincent M. Cimmino, Carol R. Bradford, Riley S. Rees, Michael S. Sabel. (2009) Prognostic Significance of a Positive Nonsentinel Lymph Node in Cutaneous Melanoma. Annals of Surgical Oncology 16:11, 2978-2984
CrossRef223
Alexander C.J. van Akkooi, Alain Spatz, Alexander M.M. Eggermont, Martin Mihm, Martin G. Cook. (2009) Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. European Journal of Cancer 45:16, 2736-2742
CrossRef224
Matthew Petitt, Ashley Allison, Tally Shimoni, Tatsuo Uchida, Sharon Raimer, Brent Kelly. (2009) Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma. Journal of the American Academy of Dermatology 61:5, 819-828
CrossRef225
Vernon K. Sondak. (2009) Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon?. Annals of Surgical Oncology 16:11, 2965-2967
CrossRef226
Lori L. Wilson. (2009) Sentinel lymph node biopsy from the vantage point of an oncologic surgeon. Clinics in Dermatology 27:6, 594-596
CrossRef227
A. Constantinidou, S. A. Afuwape, L. Linsell, T. Hung, K. Acland, C. Healy, A.-J. Ramirez, M. Harries. (2009) Informational needs of patients with melanoma and their views on the utility of investigative tests. International Journal of Clinical Practice 63:11, 1595-1600
CrossRef228
Philip E. LeBoit. (2009) What sentinel node biopsy in patients with melanoma (or patients whose doctors worry that they could have melanoma) might and might not do. Clinics in Dermatology 27:6, 588-593
CrossRef229
Michael J Sladden, Charles Balch, David A Barzilai, Daniel Berg, Anatoli Freiman, Teenah Handiside, Sally Hollis, Marko B Lens, John F Thompson, Michael J Sladden. 2009. Surgical excision margins for primary cutaneous melanoma. .
CrossRef230
Hayley M. Reynolds, Nicolas P. Smith, Roger F. Uren, John F. Thompson, P. Rod Dunbar. (2009) Three-dimensional visualization of skin lymphatic drainage patterns of the head and neck. Head & Neck 31:10, 1316-1325
CrossRef231
Annette H. Chakera, Birger Hesse, Zeynep Burak, James R. Ballinger, Allan Britten, Corrado Caracò, Alistair J. Cochran, Martin G. Cook, Krzysztof T. Drzewiecki, Richard Essner, Einat Even-Sapir, Alexander M. M. Eggermont, Tanja Gmeiner Stopar, Christian Ingvar, Martin C. Mihm, Stanley W. McCarthy, Nicola Mozzillo, Omgo E. Nieweg, Richard A. Scolyer, Hans Starz, John F. Thompson, Giuseppe Trifirò, Giuseppe Viale, Sergi Vidal-Sicart, Roger Uren, Wendy Waddington, Arturo Chiti, Alain Spatz, Alessandro Testori. (2009) EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. European Journal of Nuclear Medicine and Molecular Imaging 36:10, 1713-1742
CrossRef232
Mattijs Vries, Harald J. Hoekstra, Josette E. H. M. Hoekstra-Weebers. (2009) Quality of Life After Axillary or Groin Sentinel Lymph Node Biopsy, With or Without Completion Lymph Node Dissection, in Patients With Cutaneous Melanoma. Annals of Surgical Oncology 16:10, 2840-2847
CrossRef233
J. Meirion Thomas. (2009) Prognostic False-Positivity and Cost-Effectiveness in Sentinel Node Biopsy in Melanoma. Annals of Surgical Oncology 16:10, 2961-2961
CrossRef234
Maaike HM Oonk, Hedwig P van de Nieuwenhof, Joanne A de Hullu, Ate GJ van der Zee. (2009) The role of sentinel node biopsy in gynecological cancer: a review. Current Opinion in Oncology 21:5, 425-432
CrossRef235
Christoffer Gebhardt, Helmut Näher. (2009) Standards und Trends bei der Behandlung des malignen Melanoms. Onkopipeline 2:3, 101-113
CrossRef236
Klaus J. Busam, Rajmohan Murali, Melissa Pulitzer, Stanley W. McCarthy, John F. Thompson, Helen M. Shaw, Mary S. Brady, Daniel G. Coit, Stephen Dusza, James Wilmott, Marc Kayton, Michael LaQuaglia, Richard A. Scolyer. (2009) Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. The American Journal of Surgical Pathology 33:9, 1386-1395
CrossRef237
Thomas Jouary, Nathalie Lalanne, François Siberchicot, Anne-Sophie Ricard, Julie Versapuech, Sébastien Lepreux, Michèle Delaunay, Alain Taieb. (2009) Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma. Nature Reviews Clinical Oncology 6:9, 544-548
CrossRef238
Dominique Delbeke, Heiko Schöder, William H. Martin, Richard L. Wahl. (2009) Hybrid Imaging (SPECT/CT and PET/CT): Improving Therapeutic Decisions. Seminars in Nuclear Medicine 39:5, 308-340
CrossRef239
L. Jennings, G.M. Murphy. (2009) Predicting outcome in melanoma: where are we now?. British Journal of Dermatology 161:3, 496-503
CrossRef240
Omgo E. Nieweg. (2009) False-Negative Sentinel Node Biopsy. Annals of Surgical Oncology 16:8, 2089-2091
CrossRef241
H.P.A.M. Poos, S. Kruijff, E. Bastiaannet, R.J. van Ginkel, H.J. Hoekstra. (2009) Therapeutic groin dissection for melanoma: Risk factors for short term morbidity. European Journal of Surgical Oncology (EJSO) 35:8, 877-883
CrossRef242
James W. Jakub, Marianne Huebner, Steve Shivers, Christopher Nobo, Christopher Puleo, William S. Harmsen, Douglas S. Reintgen. (2009) The Number of Lymph Nodes Involved with Metastatic Disease Does Not Affect Outcome in Melanoma Patients as Long as All Disease Is Confined to the Sentinel Lymph Node. Annals of Surgical Oncology 16:8, 2245-2251
CrossRef243
A. Testori, P. Rutkowski, J. Marsden, L. Bastholt, V. Chiarion-Sileni, A. Hauschild, A. M. M. Eggermont. (2009) Surgery and radiotherapy in the treatment of cutaneous melanoma. Annals of Oncology 20:Supplement 6, vi22-vi29
CrossRef244
Tang Ho, Patrick J. Byrne. (2009) Evaluation and Initial Management of the Patient with Facial Skin Cancer. Facial Plastic Surgery Clinics of North America 17:3, 301-307
CrossRef245
John F Thompson, Richard A Scolyer, Richard F Kefford. (2009) Cutaneous melanoma in the era of molecular profiling. The Lancet 374:9687, 362-365
CrossRef246
Richard C. W. Martin, Rajmohan Murali, Richard A. Scolyer, Patrick Fitzgerald, Marjorie H. Colman, John F. Thompson. (2009) So-called “malignant blue nevus”. Cancer 115:13, 2949-2955
CrossRef247
, Alessandro Testori, Gian Luca De Salvo, Maria Cristina Montesco, Giuseppe Trifirò, Simone Mocellin, Giorgio Landi, Giuseppe Macripò, Paolo Carcoforo, Giuseppe Ricotti, Giuseppe Giudice, Franco Picciotto, Davide Donner, Franco Di Filippo, Javier Soteldo, Dario Casara, Mauro Schiavon, Antonella Vecchiato, Sandro Pasquali, Federica Baldini, Giovanni Mazzarol, Carlo Riccardo Rossi. (2009) Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI). Annals of Surgical Oncology 16:7, 2018-2027
CrossRef248
Brett M. Coldiron, Scott Dinehart, Howard W. Rogers. (2009) Sentinel lymph node biopsy and completion lymph node dissection for malignant melanoma are not standard of care. Clinics in Dermatology 27:4, 350-354
CrossRef249
Rikke Riber-Hansen, Jens R Nyengaard, Stephen J Hamilton-Dutoit, Pia Sjoegren, Torben Steiniche. (2009) Metastatic melanoma volume in sentinel nodes: objective stereology-based measurement predicts disease recurrence and survival. Histopathology 54:7, 796-803
CrossRef250
Andrew R. Doben, Dougald C. MacGillivray. (2009) Current Concepts in Cutaneous Melanoma: Malignant Melanoma. Surgical Clinics of North America 89:3, 713-725
CrossRef251
Jennifer A. Wargo, Kenneth Tanabe. (2009) Surgical Management of Melanoma. Hematology/Oncology Clinics of North America 23:3, 565-581
CrossRef252
Ali Cadili, Michael Smylie, John Danyluk, Kelly Dabbs. (2009) Prediction of Nonsentinel Lymph Node Metastasis in Malignant Melanoma. Journal of Surgical Research 154:2, 324-329
CrossRef253
Hidde M. Kroon, D-Yin Lin, Peter C. A. Kam, John F. Thompson. (2009) Safety and Efficacy of Isolated Limb Infusion With Cytotoxic Drugs in Elderly Patients With Advanced Locoregional Melanoma. Annals of Surgery 249:6, 1008-1013
CrossRef254
Andrew J. Spillane, Julie Winstanley, John F. Thompson. (2009) Lymph node ratio in melanoma. Cancer 115:11, 2384-2387
CrossRef255
Yan Xing, Brian D. Badgwell, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Paul F. Mansfield, Anthony Lucci, Janice N. Cormier. (2009) Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115:11, 2505-2513
CrossRef256
Rikke Riber-Hansen, Jens R. Nyengaard, Stephen J. Hamilton-Dutoit, Torben Steiniche. (2009) Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes. Cancer 115:10, 2177-2187
CrossRef257
H. Takeyama, I. Tabei, K. Uchida, T. Morikawa. (2009) Sentinel node biopsy for follicular tumours of the thyroid gland. British Journal of Surgery 96:5, 490-495
CrossRef258
Charles M. Balch, Donald L. Morton, Jeffrey E. Gershenwald, Kelly M. McMasters, Omgo E. Nieweg, Barry Powell, Merrick I. Ross, Vernon K. Sondak, John F. Thompson. (2009) Sentinel node biopsy and standard of care for melanoma. Journal of the American Academy of Dermatology 60:5, 872-875
CrossRef259
David W. Ollila, Jean H. Ashburn, Keith D. Amos, Jen Jen Yeh, Jill S. Frank, Allison M. Deal, Patricia Long, Nancy D. Thomas, Michael O. Meyers. (2009) Metastatic Melanoma Cells in the Sentinel Node Cannot Be Ignored. Journal of the American College of Surgeons 208:5, 924-929
CrossRef260
Carol L. Shields, Jerry A. Shields. (2009) Conjunctival Primary Acquired Melanosis and Melanoma: Tales, Fairy Tales, and Facts. Ophthalmic Plastic & Reconstructive Surgery 25:3, 167-172
CrossRef261
R. Dummer, A. Hauschild, G. Pentheroudakis. (2009) Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv129-iv131
CrossRef262
Amanda M. Silverio, Matthew C. McRae, Stephan Ariyan, Deepak Narayan. (2009) Management of the Difficult Sentinel Lymph Node in Patients With Primary Cutaneous Melanoma. Annals of Plastic Surgery 62:5, 564-569
CrossRef263
Hidde M. Kroon, D-Yin Lin, Peter C. A. Kam, John F. Thompson. (2009) Isolated Limb Infusion as Palliative Treatment for Advanced Limb Disease in Patients with AJCC Stage IV Melanoma. Annals of Surgical Oncology 16:5, 1193-1201
CrossRef264
Tai K. Lam, Roger F. Uren, Richard A. Scolyer, Michael J. Quinn, Kerwin F. Shannon, John F. Thompson. (2009) False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Research 19:2, 94-99
CrossRef265
(2009) Prognosis of Pretransplant Melanoma. American Journal of Transplantation 9:4, 862-862
CrossRef266
R. L. Morton, K. Howard, J. F. Thompson. (2009) The Cost-Effectiveness of Sentinel Node Biopsy in Patients with Intermediate Thickness Primary Cutaneous Melanoma. Annals of Surgical Oncology 16:4, 929-940
CrossRef267
Joseph Meirion Thomas. (2009) Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. Journal of Plastic, Reconstructive & Aesthetic Surgery 62:4, 442-446
CrossRef268
Janis M. Taube, Shanaz Begum, Chanjuan Shi, James R. Eshleman, William H. Westra. (2009) Benign Nodal Nevi Frequently Harbor the Activating V600E BRAF Mutation. The American Journal of Surgical Pathology 33:4, 568-571
CrossRef269
Binbing Yu, Lan Huang, Ram C. Tiwari, Eric J. Feuer, Karen A. Johnson. (2009) Modelling population-based cancer survival trends by using join point models for grouped survival data. Journal of the Royal Statistical Society: Series A (Statistics in Society) 172:2, 405-425
CrossRef270
Carl R. Schmidt, Katherine S. Panageas, Daniel G. Coit, Ami Patel, Mary S. Brady. (2009) An Increased Number of Sentinel Lymph Nodes Is Associated with Advanced Breslow Depth and Lymphovascular Invasion in Patients with Primary Melanoma. Annals of Surgical Oncology 16:4, 948-952
CrossRef271
Frances C. Wright, Calvin H.L. Law, Scott Berry, Andrew J. Smith. (2009) Clinically important aspects of lymph node assessment in colon cancer. Journal of Surgical Oncology 99:4, 248-255
CrossRef272
Alexandra M. Easson, Lorne E. Rotstein, David R. McCready. (2009) Lymph node assessment in melanoma. Journal of Surgical Oncology 99:4, 176-185
CrossRef273
Andrew J. Spillane, Bernard L. H. Cheung, Jonathan R. Stretch, Richard A. Scolyer, Kerwin F. Shannon, Michael J Quinn, Robyn P. M. Saw, William H. McCarthy, John F. Thompson. (2009) Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. Annals of Surgery 249:3, 473-480
CrossRef274
James M Grichnik. (2009) Hypothesis Letter: The Reason Sentinel and Lymph Node Dissections Do Not Improve Melanoma Mortality. Journal of Investigative Dermatology 129:3, 779-781
CrossRef275
Rachael L. Morton, Jonathan C. Craig, John F. Thompson. (2009) The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients. Annals of Surgical Oncology 16:3, 571-577
CrossRef276
Melanie A. Warycha, Jan Zakrzewski, Quanhong Ni, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, David Polsky, Madhu Mazumdar, Iman Osman. (2009) Meta-analysis of sentinel lymph node positivity in thin melanoma (≤1 mm). Cancer 115:4, 869-879
CrossRef277
Mark B Faries. (2009) Survival impact of sentinel lymphadenectomy. Expert Review of Dermatology 4:1, 5-8
CrossRef278
Mathew W. Ludgate, Douglas R. Fullen, Julia Lee, Lori Lowe, Carol Bradford, James Geiger, Jennifer Schwartz, Timothy M. Johnson. (2009) The atypical Spitz tumor of uncertain biologic potential. Cancer 115:3, 631-641
CrossRef279
Katharine Yao, Glen Balch, David J. Winchester. (2009) Multidisciplinary Treatment of Primary Melanoma. Surgical Clinics of North America 89:1, 267-281
CrossRef280
Adorján F. Kovács, Ulrich Stefenelli, Oliver Seitz, Marcus Middendorp, Jürgen Diener, Robert Sader, Frank Grünwald. (2009) Positive Sentinel Lymph Nodes are a Negative Prognostic Factor for Survival in T1-2 Oral/Oropharyngeal Cancer—A Long-Term Study on 103 Patients. Annals of Surgical Oncology 16:2, 233-239
CrossRef281
Ali Cadili, Greg McKinnon, Frances Wright, Wedad Hanna, Ethel MacIntosh, Zahra Abhari, Kelly Dabbs. (2009) Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. Journal of Surgical Oncologyn/a-n/a
CrossRef282
Devin McCormack, Mays Al-Shaer, Benjamin S. Goldschmidt, Paul S. Dale, Carolyn Henry, Chris Papageorgio, Kiran Bhattacharyya, John A. Viator. (2009) Photoacoustic Detection of Melanoma Micrometastasis in Sentinel Lymph Nodes. Journal of Biomechanical Engineering 131:7, 074519
CrossRef283
Ettore Minutilli, Uwe Trefzer, Eggert Stockfleth, Wolfram Sterry. (2009) Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma. Nature Clinical Practice Oncology 6:1, E1-1
CrossRef284
Susanne Carpenter, Barbara Pockaj, Amylou Dueck, Richard Gray, David Kurtz, Aleksander Sekulic, William Casey. (2008) Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?. The American Journal of Surgery 196:6, 834-843
CrossRef285
Alexander C. J. van Akkooi, Zbigniew I. Nowecki, Christiane Voit, Gregor Schäfer-Hesterberg, Wanda Michej, Johannes H. W. de Wilt, Piotr Rutkowski, Cornelis Verhoef, Alexander M. M. Eggermont. (2008) Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients. Annals of Surgery 248:6, 949-955
CrossRef286
Matthew T. Hueman, Julie R. Lange. (2008) Sentinel Lymph Node Biopsy in Melanoma. Current Treatment Options in Oncology 9:4-6, 243-250
CrossRef287
Craig L. Slingluff, Galina V. Yamshchikov, Kevin T. Hogan, Sarah C. Hibbitts, Gina R. Petroni, Eric A. Bissonette, James W. Patterson, Patrice Y. Neese, William W. Grosh, Kimberly A. Chianese-Bullock, Andrea Czarkowski, Patrice K. Rehm, Jayashree Parekh. (2008) Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines. Annals of Surgical Oncology 15:12, 3538-3549
CrossRef288
James Y. Chen, George Hruby, Richard A. Scolyer, Rajmohan Murali, Angela Hong, Patrick FitzGerald, Trang T. Pham, Michael J. Quinn, John F. Thompson. (2008) Desmoplastic neurotropic melanoma. Cancer 113:10, 2770-2778
CrossRef289
A. B. Francken, N. A. Accortt, H. M. Shaw, M. H. Colman, M. Wiener, S.-J. Soong, H. J. Hoekstra, J. F. Thompson. (2008) Follow-up schedules after treatment for malignant melanoma. British Journal of Surgery 95:11, 1401-1407
CrossRef290
Christopher P. Allan, Andrew J. Hayes, J. Meirion Thomas. (2008) ILIOINGUINAL LYMPH NODE DISSECTION FOR PALPABLE METASTATIC MELANOMA TO THE GROIN. ANZ Journal of Surgery 78:11, 982-986
CrossRef291
A.L. Dancey, B.S. Mahon, S.S. Rayatt. (2008) A review of diagnostic imaging in melanoma. Journal of Plastic, Reconstructive & Aesthetic Surgery 61:11, 1275-1283
CrossRef292
Carlo Riccardo Rossi, Sandro Pasquali, Simone Mocellin. (2008) Actual False-Negative Rate Prompts the Routine Use of Ultrasound Scan Before and After Sentinel Node Biopsy in Melanoma. Annals of Surgical Oncology 15:10, 2976-2977
CrossRef293
Patrick Terheyden, Wolfgang Tilgen, Axel Hauschild. (2008) Recent aspects of medical care of malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft 6:10, 868-880
CrossRef294
Ivan A. Ho Shon, David K.V. Chung, Robyn P.M. Saw, John F. Thompson. (2008) Guidelines for imaging in cutaneous melanoma. Nuclear Medicine Communications 29:10, 877-879
CrossRef295
Benjamin Piura. (2008) Management of primary melanoma of the female urogenital tract. The Lancet Oncology 9:10, 973-981
CrossRef296
Blazej Zbytek, J Andrew Carlson, Jacqueline Granese, Jeffrey Ross, Martin Mihm, Andrzej Slominski. (2008) Current concepts of metastasis in melanoma. Expert Review of Dermatology 3:5, 569-585
CrossRef297
Laurence Mahieu-Renard, Serge Cammilleri, Roch Giorgi, Caroline Gaudy-Marqueste, Olivier Mundler, Marie-Aleth Richard, Jean-Jacques Grob. (2008) Slow Dynamics of Lymphoscintigraphic Mapping Is Associated to the Negativity of the Sentinel Node in Melanoma Patients. Annals of Surgical Oncology 15:10, 2878-2886
CrossRef298
Fernando Gomez-Rivera, Alfredo Santillan, Andrea Barber McMurphey, George Paraskevopoulos, Dianna B. Roberts, Victor G. Prieto, Jeffrey N. Myers. (2008) Sentinel node biopsy in patients with cutaneous melanoma of the head and neck: Recurrence and survival study. Head & Neck 30:10, 1284-1294
CrossRef299
Marc Moncrieff, Richard Scolyer, John Thompson, Alison Beavis, Roger Uren, Jonathan Stretch. (2008) Correct identification of a sentinel node postselective lymphadenectomy using antimony levels. Melanoma Research 18:5, 365-366
CrossRef300
Marie-France Demierre, Michael S. Sabel, Kim A. Margolin, Adil I. Daud, Vernon K. Sondak. (2008) State of the science 60th anniversary review. Cancer 113:S7, 1728-1743
CrossRef301
Ivan A. Ho Shon, David K.V. Chung, Robyn P.M. Saw, John F. Thompson. (2008) Imaging in cutaneous melanoma. Nuclear Medicine Communications 29:10, 847-876
CrossRef302
Vernon K. Sondak. (2008) How Well Are We Taking Care of Melanoma Patients in the USA?. Annals of Surgical Oncology 15:9, 2360-2362
CrossRef303
Klaus J. Busam, Melissa Pulitzer. (2008) Sentinel Lymph Node Biopsy for Patients With Diagnostically Controversial Spitzoid Melanocytic Tumors?. Advances in Anatomic Pathology 15:5, 253-262
CrossRef304
J DEWILT, A VANAKKOOI, C VERHOEF, A EGGERMONT. (2008) Detection of melanoma micrometastases in sentinel nodes – The cons. Surgical Oncology 17:3, 175-181
CrossRef305
Ross E. Warner, Michael J. Quinn, George Hruby, Richard A. Scolyer, Roger F. Uren, John F. Thompson. (2008) Management of Merkel Cell Carcinoma: The Roles of Lymphoscintigraphy, Sentinel Lymph Node Biopsy and Adjuvant Radiotherapy. Annals of Surgical Oncology 15:9, 2509-2518
CrossRef306
Y DELPECH, C COUTANT, E DARAI, E BARRANGER. (2008) Sentinel lymph node evaluation in endometrial cancer and the importance of micrometastases. Surgical Oncology 17:3, 237-245
CrossRef307
R SCOLYER, R MURALI, I SATZGER, J THOMPSON. (2008) The detection and significance of melanoma micrometastases in sentinel nodes. Surgical Oncology 17:3, 165-174
CrossRef308
Donald L Morton, Alistair J Cochran, John F Thompson. (2008) The rationale for sentinel-node biopsy in primary melanoma. Nature Clinical Practice Oncology 5:9, 510-511
CrossRef309
Jennifer Erickson Foster, Josè M. Velasco, Tina J. Hieken. (2008) Adverse Outcomes Associated with Noncompliance with Melanoma Treatment Guidelines. Annals of Surgical Oncology 15:9, 2395-2402
CrossRef310
P.A. Baker, A.T. Sillitoe, P.R.W. Stanley, A. Williams, T. Davies, S. Stephenson. (2008) Training simulators for sentinel lymph node biopsy in malignant melanoma. Journal of Plastic, Reconstructive & Aesthetic Surgery 61:8, 976-979
CrossRef311
Cécile Pagès, Philippe Rochaix, Talal al Saati, Séverine Valmary-Degano, Serge Boulinguez, François Launay, Paul Carle, Frédéric Lauwers, Pierre Payoux, Sophie Le Guellec, Pierre Brousset, Laurence Lamant. (2008) KBA.62: a useful marker for primary and metastatic melanomas. Human Pathology 39:8, 1136-1142
CrossRef312
Jeremy B Burton, Mai Johnson, Makoto Sato, Sok Boon S Koh, David J Mulholland, David Stout, Arion F Chatziioannou, Michael E Phelps, Hong Wu, Lily Wu. (2008) Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nature Medicine 14:8, 882-888
CrossRef313
Zbigniew I. Nowecki, Piotr Rutkowski, Wanda Michej. (2008) The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3). Annals of Surgical Oncology 15:8, 2223-2234
CrossRef314
Javier Rangel, Mehdi Nosrati, Stanley P. L. Leong, Chris Haqq, James R. Miller, Richard W. Sagebiel, Mohammed Kashani-Sabet. (2008) Novel Role for RGS1 in Melanoma Progression. The American Journal of Surgical Pathology 32:8, 1207-1212
CrossRef315
Marie-Elisabeth Toubert, Pierre-Alexandre Just, Georges Baillet, Delphine Kerob, Elif Hindié, Olivier Verola, Marc Revol, Jean-Marie Servant, Nicole Basset-Seguin, Celeste Lebbé, Elena Banti, Domenico Rubello, Jean-Luc Moretti. (2008) Slow Dynamic Lymphoscintigraphy Is Not a Reliable Predictor of Sentinel-Node Negativity in Cutaneous Melanoma. Cancer Biotherapy & Radiopharmaceuticals 23:4, 443-450
CrossRef316
Matthias Rinderknecht, Michael Detmar. (2008) Tumor lymphangiogenesis and melanoma metastasis. Journal of Cellular Physiology 216:2, 347-354
CrossRef317
Rajmohan Murali, John F Thompson, Richard A Scolyer. (2008) Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. Future Oncology 4:4, 535-551
CrossRef318
Alexander M.M. Eggermont, Christiane Voit. (2008) Management of Melanoma: A European Perspective. Surgical Oncology Clinics of North America 17:3, 635-648
CrossRef319
Imke Satzger, Andre Meier, Ralf Gutzmer. (2008) The Prognostic Significance of Isolated HMB-45 or Melan-A–Positive Cells in Melanoma Sentinel Lymph Node. The American Journal of Surgical Pathology 32:7, 1107-1108
CrossRef320
Rajmohan Murali, John F. Thompson, Helen M. Shaw, Richard A. Scolyer. (2008) The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. The American Journal of Surgical Pathology 32:7, 1106-1107
CrossRef321
M Guggenheim, R Dummer, F J Jung, D Mihic-Probst, H Steinert, V Rousson, L E French, P Giovanoli. (2008) The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases. British Journal of Cancer 98:12, 1922-1928
CrossRef322
Barbara Peric, Janez Zgajnar, Nikola Besic, Marko Hocevar. (2008) Changing biology of cutaneous melanoma. Melanoma Research 18:3, 225-229
CrossRef323
Imke Satzger, Bernward Völker, Andre Meier, Alexander Kapp, Ralf Gutzmer. (2008) Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes. Annals of Surgical Oncology 15:6, 1723-1732
CrossRef324
Á. Pizarro. (2008) ¿Por qué la biopsia del ganglio centinela no aumenta la supervivencia en pacientes con melanoma?. Actas Dermo-Sifiliográficas 99:5, 323-330
CrossRef325
C. Mangas, C. Paradelo, J. Rex, C. Ferrándiz. (2008) La biopsia del ganglio centinela: su papel diagnóstico y pronóstico en el melanoma maligno. Actas Dermo-Sifiliográficas 99:5, 331-348
CrossRef326
Xiaowei Xu, Phyllis A. Gimotty, DuPont Guerry, Giorgos Karakousis, Patricia Van Belle, Haohai Liang, Katharine Montone, Terry Pasha, Michael E. Ming, Geza Acs, Michael Feldman, Stephen Barth, Rachel Hammond, Rosalie Elenitsas, Paul J. Zhang, David E. Elder. (2008) Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Human Pathology 39:6, 901-909
CrossRef327
D. Roulin, M. Matter, P. Bady, D. Liénard, O. Gugerli, A. Boubaker, L. Bron, F.J. Lejeune. (2008) Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution. European Journal of Surgical Oncology (EJSO) 34:6, 673-679
CrossRef328
Rooshdiya Z. Karim, Richard A. Scolyer, Wei Li, Vivian S. K. Yee, J Gregory McKinnon, Ling-Xi L. Li, Roger F. Uren, Stella Lam, Alison Beavis, Michael Dawson, Philip Doble, Dave S. B. Hoon, John F. Thompson. (2008) False Negative Sentinel Lymph Node Biopsies in Melanoma May Result From Deficiencies in Nuclear Medicine, Surgery, or Pathology. Annals of Surgery 247:6, 1003-1010
CrossRef329
Karl Y. Bilimoria, Charles M. Balch, David J. Bentrem, Mark S. Talamonti, Clifford Y. Ko, Julie R. Lange, David P. Winchester, Jeffrey D. Wayne. (2008) Complete Lymph Node Dissection for Sentinel Node-Positive Melanoma: Assessment of Practice Patterns in the United States. Annals of Surgical Oncology 15:6, 1566-1576
CrossRef330
Iris M. C. Ploeg, Renato A. Valdés Olmos, Bin B. R. Kroon, Omgo E. Nieweg. (2008) Tumor-Positive Sentinel Node Biopsy of the Groin in Clinically Node-Negative Melanoma Patients: Superficial or Superficial and Deep Lymph Node Dissection?. Annals of Surgical Oncology 15:5, 1485-1491
CrossRef331
J. Meirion Thomas, A. Hayes. (2008) Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma (Br J Surg 2007; 94: 1293–1299). British Journal of Surgery 95:5, 664-664
CrossRef332
A. C. J. van Akkooi, J. H. W. de Wilt, C. Verhoef, A. M. M. Eggermont. (2008) Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma. Annals of Surgical Oncology 15:5, 1547-1548
CrossRef333
Mark R. Wick. (2008) Principles of Evidence-Based Medicine as Applied to Sentinel Lymph Node Biopsies. Pathology Case Reviews 13:3, 102-108
CrossRef334
Rikke Riber-Hansen, Pia Sjoegren, Stephen Jacques Hamilton-Dutoit, Torben Steiniche. (2008) Extensive Pathological Analysis of Selected Melanoma Sentinel Lymph Nodes: High Metastasis Detection Rates at Reduced Workload. Annals of Surgical Oncology 15:5, 1492-1501
CrossRef335
Arkadiusz Spychała, Dawid Murawa, Karol Połom, Andrzej Gracz, Paweł Murawa. (2008) Sentinel Lymph Node Biopsy in Cutaneous Melanoma - Analysis of 227 Cases. Polish Journal of Surgery 80:5, 241-247
CrossRef336
Suvendu Das, Mihaela Skobe. (2008) Lymphatic Vessel Activation in Cancer. Annals of the New York Academy of Sciences 1131:1, 235-241
CrossRef337
A. C. J. van Akkooi, M. Bouwhuis, J. H. W. de Wilt, M. Kliffen, P. I. M. Schitz, A. M. M. Eggermont. (2008) Authors' reply: Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma (Br J Surg 2007; 94: 1293–1299). British Journal of Surgery 95:5, 664-665
CrossRef338
MaryClare Sarff, David Edwards, Birat Dhungel, Keith W. Wegmann, Christopher Corless, Andrew D. Weinberg, John T. Vetto. (2008) OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas. The American Journal of Surgery 195:5, 621-625
CrossRef339
Marissa Howard-McNatt, Edward A. Levine. (2008) Sentinel Node Mapping. Pathology Case Reviews 13:3, 87-94
CrossRef340
Konstantinos Lasithiotakis, Ulrike Leiter, Friedegund Meier, Thomas Eigentler, Gizela Metzler, Matthias Moehrle, Helmut Breuninger, Claus Garbe. (2008) Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112:8, 1795-1804
CrossRef341
Jennifer L. Erickson, Josè M. Velasco, Tina J. Hieken. (2008) Compliance with Melanoma Treatment Guidelines in a Community Teaching Hospital: Time Trends and Other Variables. Annals of Surgical Oncology 15:4, 1211-1217
CrossRef342
JOHN F. THOMPSON. (2008) The Value of Sentinel Node Biopsy in Patients with Primary Cutaneous Melanoma. Dermatologic Surgery 34:4, 550-555
CrossRef343
Merlin M. Guggenheim, Urs Hug, Florian J. Jung, Valentin Rousson, Matthias C. Aust, Maurizio Calcagni, Walter Künzi, Pietro Giovanoli. (2008) Morbidity and Recurrence After Completion Lymph Node Dissection Following Sentinel Lymph Node Biopsy in Cutaneous Malignant Melanoma. Annals of Surgery 247:4, 687-693
CrossRef344
Rajini Katipamula, Svetomir N Markovic. (2008) Emerging therapies for melanoma. Expert Review of Anticancer Therapy 8:4, 553-560
CrossRef345
Alexander CJ van Akkooi, Johannes HW de Wilt, Christiane Voit, Cees Verhoef, Stefan Suciu, Alexander MM Eggermont. (2008) Sentinel lymph-node false positivity in melanoma. Nature Clinical Practice Oncology 5:4, E2-E2
CrossRef346
JOHN A. ZITELLI. (2008) Sentinel Lymph Node Biopsy: An Alternate View. Dermatologic Surgery 34:4, 544-549
CrossRef347
Achilleas Thoma, Sheila Sprague, Claire Temple, Stuart Archibald. (2008) The Role of the Randomized Controlled Trial in Plastic Surgery. Clinics in Plastic Surgery 35:2, 275-284
CrossRef348
Jennifer G Pryor, Patricia A Bourne, Qi Yang, Betsy O Spaulding, Glynis A Scott, Haodong Xu. (2008) IMP-3 is a novel progression marker in malignant melanoma. Modern Pathology 21:4, 431-437
CrossRef349
Paola De Simone, Vitaliano Silipo, Pierluigi Buccini, Giustino Mariani, Samantha Marenda, Laura Eibenschutz, Angela Ferrari, Caterina Catricalà. (2008) Vulvar melanoma: a report of 10 cases and review of the literature. Melanoma Research 18:2, 127-133
CrossRef350
William M. Mendenhall, Robert J. Amdur, Stephen R. Grobmyer, Thomas J. George, John W. Werning, Steven N. Hochwald, Nancy P. Mendenhall. (2008) Adjuvant radiotherapy for cutaneous melanoma. Cancer 112:6, 1189-1196
CrossRef351
Merrick I. Ross, Jeffrey E. Gershenwald. (2008) How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Annals of Surgical Oncology 15:3, 670-673
CrossRef352
Ralf Gutzmer, Imke Satzger, Kai-Martin Thoms, Bernward Völker, Christina Mitteldorf, Alexander Kapp, Hans Peter Bertsch, Lutz Kretschmer. (2008) Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas. JDDG 6:3, 198-203
CrossRef353
P. A. Andersen, A. H. Chakera, T. L. Klausen, T. Binderup, H. S. Grossjohann, E. Friis, C. Palnaes Hansen, G. Schmidt, A. Kjaer, B. Hesse. (2008) Radiation exposure to surgical staff during F-18-FDG-guided cancer surgery. European Journal of Nuclear Medicine and Molecular Imaging 35:3, 624-629
CrossRef354
Alison Beavis, Michael Dawson, Philip Doble, Richard A. Scolyer, Roger Bourne, Ling-Xi L. Li, Rajmohan Murali, Jonathan R. Stretch, Cynthia L. Lean, Roger F. Uren, John F. Thompson. (2008) Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasma–Mass Spectrometry. Annals of Surgical Oncology 15:3, 934-940
CrossRef355
Bruce H Thiers. (2008) What's new in dermatologic therapy. Dermatologic Therapy 21:2, 142-149
CrossRef356
Alistair J Cochran, Steven J Ohsie, Scott W Binder. (2008) Pathobiology of the sentinel node. Current Opinion in Oncology 20:2, 190-195
CrossRef357
Nestor R Rigual, Saurin R Popat, Vijay Jayaprakash, Wainwright Jaggernauth, Michael Wong. (2008) Cutaneous head and neck melanoma: the old and the new. Expert Review of Anticancer Therapy 8:3, 403-412
CrossRef358
Pieter J. Tanis, Omgo E. Nieweg, Michiel W. M. van den Brekel, Alfons J. M. Balm. (2008) Dilemma of clinically node-negative head and neck melanoma: Outcome of “watch and wait” policy, elective lymph node dissection, and sentinel node biopsy—A systematic review. Head & Neck 30:3, 380-389
CrossRef359
RIKKE RIBER-HANSEN, HELENE NORTVIG ABRAHAMSEN, BOE SANDAHL SORENSEN, STEPHEN JACQUES HAMILTON-DUTOIT, TORBEN STEINICHE. (2008) Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients.. APMIS 116:3, 199-205
CrossRef360
Tzeela Cohen, Klaus J. Busam, Ami Patel, Mary S. Brady. (2008) Subungual melanoma: management considerations. The American Journal of Surgery 195:2, 244-248
CrossRef361
I. Garrido, A. Wagner, D. Gangloff, C. Chevreau, F. Courbon, V. Maisongrosse, G. Ferron, P. Martel, S. Dalac-Rat, A. Danino. (2008) Melanoma y ganglio centinela. EMC - Cirug??a Pl??stica Reparadora y Est??tica 16:2, 1-13
CrossRef362
Steven A Rosenberg. (2008) Why perform sentinel-lymph-node biopsy in patients with melanoma?. Nature Clinical Practice Oncology 5:1, 1-1
CrossRef363
Rajmohan Murali, Raghwa N. Sharma, John F. Thompson, Jonathan R. Stretch, C. Soon Lee, Stanley W. McCarthy, Richard A. Scolyer. (2008) Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). Annals of Surgical Oncology 15:1, 302-309
CrossRef364
F. Roka, P. Mastan, M. Binder, I. Okamoto, M. Mittlboeck, R. Horvat, H. Pehamberger, E. Diem. (2008) Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. European Journal of Surgical Oncology (EJSO) 34:1, 82-88
CrossRef365
Sherry J. Lim, Barry W. Feig, Huamin Wang, Kelly K. Hunt, Miguel A. Rodriguez-Bigas, John M. Skibber, Vickie Ellis, Karen Cleary, George J. Chang. (2008) Sentinel Lymph Node Evaluation Does Not Improve Staging Accuracy in Colon Cancer. Annals of Surgical Oncology 15:1, 46-51
CrossRef366
J Meirion Thomas. (2008) Prognostic false-positivity of the sentinel node in melanoma. Nature Clinical Practice Oncology 5:1, 18-23
CrossRef367
Grant W. Carlson, Andrew J. Page, Cynthia Cohen, Douglas Parker, Ron Yaar, Anya Li, Andrea Hestley, Keith A. Delman, Douglas R. Murray. (2008) Regional Recurrence After Negative Sentinel Lymph Node Biopsy for Melanoma. Transactions of the ... Meeting of the American Surgical Association 126, 28-36
CrossRef368
Kong-Bing Tan, Marc Moncrieff, John F. Thompson, Stanley W. McCarthy, Helen M. Shaw, Michael J. Quinn, Ling-Xi Lawrence Li, Kerry A. Crotty, Jonathan R. Stretch, Richard A. Scolyer. (2007) Subungual Melanoma. The American Journal of Surgical Pathology 31:12, 1902-1912
CrossRef369
Gregor Schäfer-Hesterberg, Alfred Schoengen, Wolfram Sterry, Christiane Voit. (2007) Use of ultrasound to early identify, diagnose and localize metastases in melanoma patients. Expert Review of Anticancer Therapy 7:12, 1707-1716
CrossRef370
Ilkka Koskivuo, Lauri Talve, Pia Vihinen, Maija Mäki, Tero Vahlberg, Erkki Suominen. (2007) Sentinel Lymph Node Biopsy in Cutaneous Melanoma: A Case-Control Study. Annals of Surgical Oncology 14:12, 3566-3574
CrossRef371
Christof Phillipe Erickson. (2007) Prognostic Factors in Cutaneous Melanoma. Pathology Case Reviews 12:6, 225-229
CrossRef372
Mohammed Kashani-Sabet. 2007. Melanoma. .
CrossRef373
Alison Z. Young, George F. Murphy. 2007. Skin. .
CrossRef374
A. Tejera-Vaquerizo, M.V. Barrera-Vigo, I. Fernández-Canedo, N. Blázquez-Sánchez, M. Mendiola-Fernández, A. Fernández-Orland, R. Bosch-García, M. de Troya-Martín, E. Herrera-Ceballos. (2007) Estudio temporal de los diferentes patrones metastásicos en la progresión del melanoma cutáneo. Actas Dermo-Sifiliográficas 98:8, 531-538
CrossRef375
Charles F. Levenback. (2007) Status of sentinel lymph nodes in cervical cancer. Gynecologic Oncology 107:1, S18-S19
CrossRef376
A. C. J. van Akkooi, M. G. Bouwhuis, J. H. W. de Wilt, M. Kliffen, P. I. M. Schmitz, A. M. M. Eggermont. (2007) Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. British Journal of Surgery 94:10, 1293-1299
CrossRef377
Gerda Topar, Bernhard Zelger. (2007) Assessment of value of the sentinel lymph node biopsy in melanoma in children and adolescents and applicability of subcutaneous infusion anesthesia. Journal of Pediatric Surgery 42:10, 1716-1720
CrossRef378
Anton J. Bilchik, Dave S. B. Hoon, Sukamal Saha, Roderick R. Turner, David Wiese, Maggie DiNome, Kazuo Koyanagi, Martin McCarter, Perry Shen, Douglas Iddings, Steven L. Chen, Maria Gonzalez, David Elashoff, Donald L. Morton. (2007) Prognostic Impact of Micrometastases in Colon Cancer. Annals of Surgery 246:4, 568-577
CrossRef379
Randall P. Scheri, Richard Essner, Roderick R. Turner, Xing Ye, Donald L. Morton. (2007) Isolated Tumor Cells in the Sentinel Node Affect Long-Term Prognosis of Patients with Melanoma. Annals of Surgical Oncology 14:10, 2861-2866
CrossRef380
Christine S. Landry, Kelly M. McMasters, Charles R. Scoggins. (2007) The evolution of the management of regional lymph nodes in melanoma. Journal of Surgical Oncology 96:4, 316-321
CrossRef381
Donald L. Morton, Randall P. Scheri, Charles M. Balch. (2007) Can Completion Lymph Node Dissection Be Avoided for a Positive Sentinel Node in Melanoma?. Annals of Surgical Oncology 14:9, 2437-2439
CrossRef382
C. Caracò, U. Marone, E. Celentano, G. Botti, N. Mozzillo. (2007) Impact of False-Negative Sentinel Lymph Node Biopsy on Survival in Patients with Cutaneous Melanoma. Annals of Surgical Oncology 14:9, 2662-2667
CrossRef383
James E. Gervasoni Jr., Samer Sbayi, Blake Cady. (2007) Role of Lymphadenectomy in Surgical Treatment of Solid Tumors: An Update on the Clinical Data. Annals of Surgical Oncology 14:9, 2443-2462
CrossRef384
G. Palmieri, M. Casula, M.C. Sini, P.A. Ascierto, A. Cossu. (2007) Issues affecting molecular staging in the management of patients with melanoma. Journal of Cellular and Molecular Medicine 11:5, 1052-1068
CrossRef385
A. Neil Crowson, Cynthia Magro, Martin C. Mihm. (2007) Unusual histologic and clinical variants of melanoma: Implications for therapy. Current Oncology Reports 9:5, 403-410
CrossRef386
Lakshi M. Aldredge. (2007) The Role of Sentinel Node Biopsy in Patients with Cutaneous Melanoma. Nursing Clinics of North America 42:3, 379-392
CrossRef387
David M. Kushner, Joseph P. Connor, Michael A. Wilson, G. Reza Hafez, Richard J. Chappell, Sarah L. Stewart, Ellen M. Hartenbach. (2007) Laparoscopic sentinel lymph node mapping for cervix cancer—A detailed evaluation and time analysis. Gynecologic Oncology 106:3, 507-512
CrossRef388
Arata Tsutsumida, Hiroshi Furukawa, Yuhei Yamamoto, Katsumi Horiuchi, Tetsunori Yoshida, Hidehiko Minakawa, Satoru Fujii, Naoki Murao, Hiroaki Kuwahara, Toshiyuki Minamimoto, Hirotaka Fujioka, Taisuke Sakamoto, Toyohiro Honma. (2007) Sentinel node biopsy versus elective lymph node dissection in patients with cutaneous melanoma in a Japanese population. International Journal of Clinical Oncology 12:4, 245-249
CrossRef389
C. Voit, A. Schoengen, G. Schäfer-Hesterberg. (2007) Risikoadaptierte Nachsorge von Melanompatienten. Der Onkologe 13:8, 735-739
CrossRef390
Claire Sibon, Sophie Chagnon, Arnold Tchak??rian, Marie-Lise Bafounta, Christine Longvert, Thierry Clerici, Ute Zimmermann, Philippe Saiag. (2007) The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Research 17:4, 233-237
CrossRef391
T.K. Eigentler, L.-O. Mügge, A. Bembenek, C. Garbe. (2007) Kutanes Melanom. Der Onkologe 13:8, 745-758
CrossRef392
RACHEL E. SAHN, PEARON G. LANG. (2007) Sentinel Lymph Node Biopsy for High-Risk Nonmelanoma Skin Cancers. Dermatologic Surgery 33:7, 786-793
CrossRef393
Christopher K. Bichakjian, Lori Lowe, Christopher D. Lao, Howard M. Sandler, Carol R. Bradford, Timothy M. Johnson, Sandra L. Wong. (2007) Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management. Cancer 110:1, 1-12
CrossRef394
Paul B. Chapman. (2007) Detection of melanoma cells in sentinel lymph nodes by PCR is not yet ready for prime time. Pigment Cell Research 0:0, 070629131525001-???
CrossRef395
Jason S. Gold, David P. Jaques, Klaus J. Busam, Mary S. Brady, Daniel G. Coit. (2007) Yield and Predictors of Radiologic Studies for Identifying Distant Metastases in Melanoma Patients with a Positive Sentinel Lymph Node Biopsy. Annals of Surgical Oncology 14:7, 2133-2140
CrossRef396
Emily Newton-Dunn, Matthew Kok-Hao Hong, Michael Kok-Yee Hong, Christopher Stone. (2007) What is the role of CT staging in the management of patients with clinical stage 1 and 2 malignant melanoma?. European Journal of Plastic Surgery 30:1, 7-9
CrossRef397
Michael S. Sabel, Kent A. Griffith, Alisha Arora, Josef Shargorodsky, Dan G. Blazer, Riley Rees, Sandra L. Wong, Vincent M. Cimmino, Alfred E. Chang. (2007) Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 141:6, 728-735
CrossRef398
E VERDIER, I AUQUITAUCKBUR, P YOUNG, C CORVEN, J CHOMANT, P COURVILLE, P VERA, P MILLIEZ, P JOLY. (2007) Complications liées à l’exérèse du ganglion sentinelle dans le mélanome. Annales de Dermatologie et de Vénéréologie 134:5, 439-442
CrossRef399
M.H.E. Doting, M. de Vries, J.T. Plukker, P.L. Jager, W.J. Post, A.J. Suurmeijer, H.J. Hoekstra. (2007) Response: The value of sentinel lymph node biopsy in the management of head and neck melanoma. Journal of Surgical Oncology 95:6, 523-523
CrossRef400
Jeffrey E Gershenwald, Merrick I Ross. (2007) Is sentinel-node biopsy superior to nodal observation in melanoma?. Nature Clinical Practice Oncology 4:5, 278-279
CrossRef401
Donald L. Morton, Alistair J. Cochran, John F. Thompson. (2007) Authors??? Response to a Letter to the Editor Re: Sentinel Node Biopsy for Early-Stage Melanoma. Annals of Surgery 245:5, 828-829
CrossRef402
K.K. DHAR, N. DAS, D.A. BRINKMAN, J.L. BEYNON, R.P. WOOLAS. (2007) Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. International Journal of Gynecological Cancer 17:3, 720-723
CrossRef403
Rachel E. Emery, Jeffery S. Stevens, Robert W. Nance, Christopher L. Corless, John T. Vetto. (2007) Sentinel node staging of primary melanoma by the “10% rule”: pathology and clinical outcomes. The American Journal of Surgery 193:5, 618-622
CrossRef404
Claus Garbe, Thomas K. Eigentler. (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006*. Melanoma Research 17:2, 117-127
CrossRef405
Cuneyt Tatlidil, Winston S Parkhill, Carman A Giacomantonio, Wenda L Greer, Steven F Morris, Noreen M G Walsh. (2007) Detection of tyrosinase mRNA in the sentinel lymph nodes of melanoma patients is not a predictor of short-term disease recurrence. Modern Pathology 20:4, 427-434
CrossRef406
(2007) Scientific Surgery. British Journal of Surgery 94:4, 518-518
CrossRef407
Adam I Riker, Soroosh Radfar, SuHu Liu, Yixiang Wang, Hung T Khong. (2007) Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opinion on Biological Therapy 7:3, 345-358
CrossRef408
Jedd D Wolchok, Yvonne M Saenger. (2007) Current topics in melanoma. Current Opinion in Oncology 19:2, 116-120
CrossRef409
Allan C Halpern, Jocelyn A Lieb. (2007) Early melanoma diagnosis: a success story that leaves room for improvement. Current Opinion in Oncology 19:2, 109-115
CrossRef410
(2007) Sentinel-Node Biopsy in Melanoma. New England Journal of Medicine 356:4, 418-421
Full Text411
Vincenzo De Giorgi, Genny Leporatti, Daniela Massi, Giulia Lo Russo, Serena Sestini, Mario Dini, Torello Lotti. (2007) Outcome of Patients with Melanoma and Histologically Negative Sentinel Lymph Nodes: One Institution’s Experience. Oncology 73:5-6, 401-406
CrossRef412
B. Guillot, A. Bernard. (2007) Les résultats de l’étude de Morton doivent-ils modifier les recommandations de prise en charge du mélanome ?. Annales de Dermatologie et de Vénéréologie 134:1, 17-19
CrossRef413
P.G. Lang. (2007) Sentinel-Node Biopsy or Nodal Observation in Melanoma. Yearbook of Dermatology and Dermatologic Surgery 2007, 359-361
CrossRef414
Laura L. Kruper, Francis R. Spitz, Brian J. Czerniecki, Douglas L. Fraker, Anne Blackwood-Chirchir, Michael E. Ming, David E. Elder, Rosalie Elenitsas, DuPont Guerry, Phyllis A. Gimotty. (2006) Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107:10, 2436-2445
CrossRef415
Adam I Riker, Lisa Kirksey, Lee Thompson, Amy Morris, C Wayne Cruse. (2006) Current surgical management of melanoma. Expert Review of Anticancer Therapy 6:11, 1569-1583
CrossRef416
Balch, Charles M., Cascinelli, Natale, . (2006) Sentinel-Node Biopsy in Melanoma. New England Journal of Medicine 355:13, 1370-1371
Full Text
- Letters
